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Chapter 1: Introduction 
1.1 Motivation and Outlook 
In the human body and the other natural environments, bacteria aggregate to form 
living communities of microbes, called biofilms, composed of interacting bacteria and an 
extracellular matrix (ECM) of adhesins and polysaccharides [1].  Once formed, biofilms 
produce harmful toxins that have been linked to as many as 65% of all microbial 
infections within the human body, making them of considerable relevance in clinical 
fields [2].  The treatment of biofilms is a medical challenge, often requiring 500-5000 
times the concentration of antibiotics for effective treatment compared to bacteria in 
planktonic suspension [3].  The presence of the ECM limits molecular diffusion within 
the biofilm, making antibiotics less effective by limiting the number of bacterial cells 
they encounter and thus decreasing the overall efficacy of these drugs [1].  A second 
factor complicating treatment arises due to the ability of bacteria in close proximity to 
readily exchange genes such as those that promote antibiotic resistance, thereby 
developing advanced levels of drug resistance and requiring more aggressive antibiotic 
therapies for effective treatment [4].  The frequent use of high antibiotic doses is 
problematic as it increases the risk of harmful side effects and promotes the proliferation 
of multidrug resistant bacteria.  The extent to which bacterial biofilms are clinically 
relevant and the difficulties associated with treating infections of this type provide strong 
motivation for the development of new methods for the early detection and treatment of 
bacterial biofilms.  As a result, current medical research displays a strong focus in this 
area, thus providing a need for new systems capable of in vitro bacterial biofilm testing to 
determine the efficacy of candidate pharmaceutical treatments.       
 2 
With the current market for antimicrobial treatments totaling well over US $25 
billion, there is considerable interest and investment in the field aimed at the development 
of these new antibiotics [5].  In addition to these financial incentives, the emergence of 
antibiotic resistance to most common treatments is problematic and therefore motivates a 
need for new drugs that can treat infections within the human body, such as those caused 
by bacterial biofilms.  The development of new methods to perform efficient drug 
screening processes can reduce the cost and time-to-market of these new treatments, 
thereby having far-reaching effects including increased treatment efficacy and patient 
survival rates, and increased access to medications through reductions in cost.     
Current methods of antibiotic evaluation typically employ macroscale reactors for 
biofilm growth, with fluorescence labeling and microscopy constituting the primary 
means of determining candidate drug efficacy [6, 7].  The high cost, low throughput, and 
large sample volumes required for these techniques limits the pace of current drug 
discovery efforts.  This, in turn, points to a strong need for novel drug screening methods 
that utilize low-cost parallel testing and microscale sample-volumes in order to increase 
the economic and time-to-market efficiency of drug development.  
A factor currently limiting the development of new biomedical systems is 
founded in the complex nature of biological systems.  Such complexity often hinders the 
development of new technologies, as biologists, clinicians, and engineers exhibit a 
disconnect in expertise that inhibits the effective design of new systems [8, 9].  Recent 
advancements in the field of systems engineering have begun to suggest possible 
solutions to this dichotomy by offering strategies to integrate the separate realms of 
biology and engineering [8].  Visual and mathematical modeling methods that 
 3 
incorporate abstraction, standardization, and decoupling allow for engineering and 
biological concerns to be understood by both domains, thus facilitating a transition to 
unified system design [8, 10].  As a case in point, the field of microbiology has already 
begun to benefit from this union by adapting various microtechnologies to address the 
specific needs of biological applications that are not traditionally addressable by 
macroscale systems [11].  Emerging clinical drug screening methods have begun to 
utilize microfabrication techniques that were initially developed for use in the integrated 
circuits (IC) industry in order to benefit from the capabilities of devices on the microscale 
[11].  Specifically, recent work has suggested that the use of soft lithography and 
microfluidic systems, those utilizing microliter-scale fluid volumes as opposed to the 
milliliter-scale volumes of macroscale systems, have numerous advantages over current 
methods.  The low fabrication cost, highly parallel throughput, and precise environmental 
control capabilities of these devices gives strong support for their use in drug screening 
applications and is a principle demonstration of the ways in which systems engineering 
approaches are currently finding new ways of integrating engineering and biological 
domains to more effectively meet the needs of the clinical world [11].   
Future advances in the field of microbiology will involve the integration of these 
microscale techniques in order to address the sensing and monitoring needs of the field.  
To date, the majority of microfluidic-based drug screening systems continue to utilize the 
same complex external instrumentation often used in macroscale methods, such as 
confocal microscopy, for the evaluation of biofilms [6].  Recent advancements in 
microfabrication techniques, specifically those relating to soft lithography and 
bioengineered micro-electro-mechanical systems (BioMEMS) have begun to allow for 
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the integration of biocompatible microfluidic systems with sensors and actuators capable 
of bacterial growth monitoring [11, 12].  A major focus of this work is in the integration 
of such methods through a systematic approach that enables novel functionality not 
currently achievable using established drug discovery methods.   
Looking forward, a more detailed understanding of bacterial biofilms as 
biological systems and more efficient ways of developing antibacterial treatments are 
needed if the current efficacy of drugs is to be maintained or improved in coming years.  
The collaboration of microfabrication and IC technologies with the fields of 
microbiology and biopharmaceuticals enables this transition due to the complimentary 
length scales shared between the two domains and the high-throughput, low-volume 
advantages of batch-fabricated micro/nano systems [11-13].  The use of systems 
engineering principles to bridge the gap between these two regimes facilitates a 
synergistic effort that can result in a unified approach to treating and studying bacterial 
biofilms and related infections [10, 11].    
 
1.2 Thesis Accomplishments 
 The primary objective of this research is the design, fabrication, and 
characterization of a microfluidics based system for the in situ monitoring of bacterial 
biofilms.  Systems engineering principles are used to drive a unified device design 
supporting both the engineering and biological requirements of the system.  MEMS 
fabrication technologies are used to structure microfluidic chambers for the controlled 
growth and treatment of biofilms for drug screening applications.  The integration of the 
microfluidic structures with linear array charge-coupled devices (CCD) enables temporal 
tracking of biofilm development via the optical density (OD) properties of the film as its 
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cell density increases [14].  Such an optical method has been explored previously within 
our group and demonstrates an ability to perform real-time monitoring of changes in 
biofilm biomass due to growth and treatment [6].  The added spatial resolution of the 
photopixel array allows for biofilm monitoring with respect to both average biofilm 
optical density as well as localized morphology, an enhanced capability over previous 
work.  This sensing method provides a non-invasive, label-free method of continuous 
bacterial biofilm growth and treatment monitoring that is currently unachievable using 
established methods.  To enable parallel throughput of biofilm experiments in a full 
microsystem, multiple devices are integrated in parallel with the capability of providing 
independent treatments to each biofilm sample.  The realized microsystem achieves high-
throughput, minimally invasive biofilm testing for the screening of multiple candidate 
drugs in a single device.   
 A second objective of this work focuses on the demonstration of a novel on-chip 
bacterial biofilm treatment method utilizing an enhanced bioelectric effect to achieve 
improved antibiotic efficacy.  In order to validate the superpositioned bioelectric effect 
(SP BE) treatment method for microscale environments, microfabricated electrodes are 
integrated with the microfluidic device to supply superpositioned (SP) AC and DC 
electric fields to the biofilms in the presence of antibiotics.  This combinatorial biofilm 
treatment method expresses improved efficacy over antibiotics alone, while 
demonstration at the microscale in a lab-on-a-chip device encourages the use of this 
method for potential clinical applications.  Importantly, the use of the microfluidic 
biofilm monitoring platform for such diverse drug screening applications verifies its 
flexibility as a tool for the evaluation of prospective antimicrobial treatments.   
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1.3 System Overview 
 The crux of this work focuses on the design, fabrication, and testing of the 
microsystem presented in figure 1.1, termed the microfluidic biofilm observation, 
analysis, and treatment (Micro-BOAT) system, to achieve continuous biofilm monitoring 
and simultaneous on-chip treatment using the SP BE.   
 
Figure 1.1: Three-dimensional schematic of the developed microsystem. 
 
The developed system addresses many of the shortcomings of current biofilm monitoring 
techniques by offering real-time, non-invasive, and label-free measurements of biofilms 
through an optical density approach.  Additionally, the use of microfluidic reactors to 
grow, maintain, and treat experimental biofilms provides a major advantage of this 
system over macroscale methods by reducing assay times as well as the necessary 
volumes of high-cost reagents.  Implementation of the novel SP BE treatment method on-
chip demonstrates the flexibility of this microfluidic microsystem for various biological 
and drug screening applications, establishing it as a new tool for a variety of biofilm 
studies.   
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 Systems engineering principles realized through the use of a unique biomedical 
device design paradigm, referred to as a design “platform” in this work, enable the 
efficient and flexible system design architecture achieved in the Micro-BOAT system 
[15].  This platform provides a conceptual framework for the development of many 
classes of biomedical devices that is readily adapted to the biofilm analysis application 
addressed in this work.  The platform allows for the segmentation of various modules of 
the biomedical system and hence a system-level analysis linking device requirements to 
device functionality and structure.  The Micro-BOAT tool resulting from this systems-
driven design process features an optical sensing mechanism, a microfluidic growth 
module, supporting software, on-chip supporting electronics, and integrated electrodes 
enabling the novel SP BE therapy, thereby representing a full system for biofilm 
investigations and the testing of novel treatment methods.  
The system itself utilizes commercial off-the-shelf (COTS) components integrated 
on a printed circuit board (PCB) with a biocompatible microfluidic device module to 
realize the full system architecture.  CCD and supporting electronic components are 
integrated in parallel on a single PCB to enable six experiments on a single chip.  
Microfluidic growth chambers formed in polydimethylsiloxane (PDMS) and gold 
electrode structures for applying the enhanced bioelectric effect (SP BE) are constructed 
using microfabrication techniques on a transparent Pyrex
TM
 substrate.  CCD components 
are aligned to their corresponding microfluidic chambers to enable spatiotemporal optical 
density measurement.  Diffused light provided by a panel of light emitting diodes (LED) 
is absorbed by biofilms formed in the microfluidic chambers and transmitted to each 
CCD, where changes in CCD output signal correspond to changes in biofilm optical 
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density, a proven indicator of biofilm biomass.  Bacterial cultures, biofilm growth media, 
and antibiotics are supplied to the device’s microfluidic channels via inlets in the PDMS 
bulk, with an external syringe pump providing control of sample fluid flow.  An external 
power supply and function generators drive the device operation and application of the 
electric field for the enhanced bioelectric effect.  Device readout is achieved via PCB-
mounted connectors, shown in black in Figure 1.1, with an accompanying data 
acquisition card and supporting software uniquely designed for this application.     
A fully fabricated and assembled system is capable of running parallel biofilm 
experiments featuring six unique biofilms, each with their own accompanying treatment, 
for long experimental periods in excess of several days.  Treatment experiments are 
conducted by initially forming bacterial biofilms within the microfluidic chambers before 
providing the various treatments.  Optical density measurements are obtained in real-time 
in order to characterize localized and average changes in biofilm optical density, thereby 
enabling full imaging of the highly variant biofilm structures.  Comparisons between 
multiple treatments can determine the relative efficacy of each in removing bacterial 
biofilms and hence bacterial biofilm infections.   
 
1.4 Review of Related Work  
 This section provides background relevant to bacterial biofilms and the current 
state-of-the-art with respect to biofilm growth and monitoring techniques.  A review of 
relevant MEMS microfabrication techniques is provided with a concentration on 
microfluidic and lab-on-a-chip devices for biomedical applications.  The section 
concludes with information relevant to the SP BE utilized as an on-chip biofilm treatment 
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in this work, as well as insight into the methods by which systems engineering can 
benefit the development of biomedical microsystems.  Cumulatively, this review 
establishes a starting point and motivation for the system development presented in this 
work, which is addressed by the design considerations and system-level development 
presented in Chapter 2.   
 
1.4.1. Bacterial Biofilms 
Bacterial biofilms have displayed a remarkable propensity to form under nearly 
any set of environmental conditions and preferentially attach to any number of surfaces in 
the natural world, with early fossil records indicating the growth of biofilms as far as 
~3.25 billion years ago [16].  While much of the work to date has been concerned with 
the development of bacterial biofilms with regards to macroscopic applications, where 
biocorrosion and biofouling are of interest, recent work in the field of microbiology has 
revealed a number of clinical applications in which bacterial biofilms are of particular 
relevance due to their ability to cause dangerous infections in the human body [2, 16-20].  
Their prevalence in infections related to biomedical implants and intravenous tubing 
including heart valves, artificial hips, and catheters has been well documented [2, 4, 21, 
22].  Additionally, they have been shown to attack body tissues and organs through 
various mechanisms, including the lungs, teeth, gums, ears, and urogenital tract [2].  
Advances in technology have enabled the study of these microorganisms at the cellular 
and sub cellular levels, allowing for a greater understanding of biofilms as complex 
biological systems whose level of intricacy are often compared to the tissues and organs 
of higher organisms [1, 23].  
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 Biofilms are generally defined as a heterogeneous community of bacterial cells 
that attach to a substrate and, upon achieving a certain cell density, begin to form a 
polymeric matrix of polysaccharides, adhesins, and bacterial cells as a means of 
protective growth against hostile environmental conditions [4, 6, 23].  A model of 
development for bacterial biofilms is presented in Figure 1.2, where biofilm growth 
initiates with the attachment of planktonic cells to a surface. 
 
Figure 1.2: Flow diagram illustrating the development cycle of bacterial biofilms [24](1) 
Planktonic bacteria reversibly adhere to a surface, (2) Bacteria begin to produce ECM 
and become irreversibly attached to the substrate, (3) and (4) Separate colonies of 
bacteria develop into mature biofilms, and (5) Biofilms propagate and spread. 
As bacteria cells accumulate and attach to the surface, individual cells are capable of 
determining their localized density by monitoring the uptake and release of autoinducer 
communication molecules in a process known as quorum sensing [18, 25].  Once the 
bacteria have reached a threshold population, or quorum, the immature biofilm begins to 
produce a matrix of exoproteins and sister cells that are bound within the biofilm ECM.  
The development of biofilm microcolonies continues until a robust and mature biofilm 
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has been realized consisting of single bacterial cells and microcolonies of sister cells 
encased in a hydrated matrix of bacteria, exopolysaccharides, and extraneous 
macromolecules [23, 26-28].  As the biofilm reaches this mature state, it continues to 
proliferate through the shearing and spread of individual biofilm clumps (clumping and 
surface dispersal) as well as the release of individual bacterial cells from the biofilm mass 
through seeding (swarming/seeding dispersal) [16].  The development cycle repeats, 
thereby increasing the overall biofilm mass, and in clinical applications, the spread of the 
bacterial infection.   
 As biofilms mature, they begin to express specific genes that allow for increased 
protection against harsh environments as well as the continued development of a robust 
biofilm structure [29].  In order to facilitate the movement of nutrients, oxygen, and water 
throughout the biofilm, transport channels are formed to maintain the vitality of biofilm 
microcolonies that would otherwise die due to nutrient depletion [16].  In response to 
external environmental conditions such as fluid shear stress and available nutrient 
concentration, bacterial films develop a colony structure that facilitates a healthy and 
vigorous biofilm.  Biofilms formed in regions of high fluid shear stress tend to form thin, 
dense colony striations, while those formed in regions of slower flows demonstrate 
fingerlike formations [16].  For both thin-film and fingerlike structures, most biofilms are 
supported by the mechanics shown in Figure 1.3, where advection, diffusion, and 
attachment/detachment processes determine overall biofilm viability and structure [30].  
Diffusion and advection maintain the necessary levels of oxygen and nutrient 
concentrations within the biofilm in order to support embedded bacterial cells, while the 
attachment, detachment, and growth/decay of individual cells determines the overall mass 
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and maturity of the biofilm as a whole.  Additional gene exchange within the biofilm 
further promotes the specialized function of individual bacterium to enhance the benefits 
of colony formation [25].   
 
Figure 1.3: Various mechanisms determine growth and nutrient transfer in biofilms [30]. 
A close-up view of a biofilm structure, shown with level liquid-film boundary for 
simplicity, reveals that advection and diffusion mechanisms at the molecular level are 
vital to biofilm growth. 
 
 The complexity and diversity of biofilm-associated infections makes the use of 
traditional approaches to new treatment development exceedingly difficult and time 
consuming.  In order to increase knowledge of the biological system as well as streamline 
the development process for new bactericidal therapies, efforts in the areas of 
bioengineering, systems biology, and systems engineering are focusing on the 
development of new mathematical models and device systems in order to advance the 
current state-of-the-art.  These works directly address the major factors outlined here with 
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respect to biofilm growth and treatment: surface attachment, quorum sensing and gene 
expression, fluid flow shear stress, and nutrient/toxin concentrations and diffusion.  
Utilizing the Micro-BOAT system developed in this work, many of these factors can be 
controlled to a high level of precision, thereby enabling others to be examined for 
applications in both biological science and biofilm treatment development.  
 
1.4.2 Antibiotic Treatments and Biofilm Antibiotic Resistance   
In this work, the developed microsystem is employed for the evaluation of a novel 
bacterial biofilm treatment mechanism and its level of efficacy with respect to other 
antibiotic therapies.  Traditional antibiotic therapies are well-founded and engineered to 
affect specific bacteria in effective ways to either halt their ability to reproduce and 
function or to be eradicated.  Since the new method explored in this work utilizes such 
antibiotics in conjunction with external electric fields, an understanding of the 
mechanism of these drugs is useful for understanding how the proposed mechanism can 
aid antibiotic efficacy.   
From a high level, antibiotics function by either stopping bacterial reproduction 
(bacteriostatic) or by interrupting vital bacterium functions, thus resulting in bacteria 
death (bactericidal) [31].  Within these groups, the vast majority creates either 
bactericidal or bacteriostatic effects by affecting one of three aspects of the bacteria: (1) 
the cell wall or membrane, (2) the synthesis and use of essential enzymes, or (3) the 
synthesis of necessary proteins within bacteria [31].  Each antibiotic is specifically 
designed to affect bacteria in one of these three ways by entering the cell (or in some 
 14 
cases binding to its exterior wall or membrane) and binding to specific receptors or 
producers within the bacterium, thereby hindering normal bacterium functions.    
While the mechanisms of antibiotics are highly effective in planktonic bacteria, 
the emergent properties of bacterial colonies form a basis for numerous clinical 
challenges with respect to bacterial infection treatment [32, 33].  Bacterial biofilms 
preferentially adhere to inert surfaces within the human body, such as dead tissue and 
medical implants.  Once established, biofilms demonstrate enhanced antibiotic resistance 
by various mechanisms [34].  The presence of the polysaccharide matrix reduces 
antibiotic diffusion rates by a factor of two to three within the biofilm and even limits the 
ability of the antibiotic molecules to enter the biofilm structure, thereby diminishing 
biocidal effects.  Additionally, bacteria within the extracellular matrix coordinate 
responses to the environmental stresses of antibiotic treatment by slowing or altering 
metabolic processes, altering gene expression, and developing increased populations of 
persister cells, all with the purpose of defending against antimicrobial treatments [34].  
Biofilms developing within the human body tend to grow slowly, with overt signs of 
infection often not being visible until the biofilm has reached relative maturity.  The 
production of toxic antigens by sessile bacteria cells stimulates the production of 
antibodies by the host’s immune system, however, this response is often insufficient for 
reduction of the bacterial infection [35].   
As a result, antibiotic therapy is typically used to augment the antimicrobial effect 
of these antibodies by exploiting various weaknesses in bacterial cell functionality.  
While such treatments are effective in removing the majority of bacteria, small 
populations of antibiotic resistant bacteria frequently remain after the treatment has ended 
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and the production of antibodies has subsided, allowing bacterial infections to redevelop 
in the host organism.  Such recursions often require surgical removal of the infection for 
decisive treatment, procedures that incur their own risk and cost and thus drive progress 
in novel treatment methods for bacterial infections [36].    
 
1.4.3 Bioelectric Effect for Enhanced Antibiotic Efficacy 
In order to increase the effectiveness of antibiotic treatment, much work has been 
performed both in the development of new antibiotic types as well as in developing 
methods of increasing the efficacy of currently available drugs.  Previous studies have 
shown that the biocidal effects of antibiotics can be increased if they are used in the 
presence of an electric field, commonly referred to as the “bioelectric effect” [37-43].  
While the mechanism behind this level of increased treatment is not yet fully understood, 
it is currently believed that the application of alternating currents (AC) and direct currents 
(DC) have different effects upon bacteria under antibiotic treatment, both of which show 
an increase in efficacy of supplied drugs.  The application of AC electric fields to 
bacterial cells results in molecular vibrations at the bacterial cell wall.  Such vibration 
increases the permeability of the cells themselves, allowing for antibiotics to more readily 
penetrate and affect cells [44].  DC electric fields applied to bacterial cells in the presence 
of antibiotics have also shown increases in treatment efficacy, which is currently 
attributed to the ability of the induced electric field to apply a force upon antibiotic 
molecules and bacteria and thus increase the rate at which the cells are exposed to the 
biocides [44].  Many bacteria (both gram-negative and gram-positive) display a net 
negative charge at their surface, while antibiotic molecules and other molecules within 
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bacterial growth solutions often display a slight positive charge.  The electrophoretic 
forces of the DC electric field on these molecules create gradients of antibiotic molecules 
and pH, which results in an increase in the efficacy of the applied drugs.  Recent work in 
our group by Kim et al. utilizes a superposition of these two electric fields in macroscale 
systems showing a 400 times increase in treatment efficacy versus standard antibiotic 
treatments while maintaining electric fields below those that would induce hydrolysis of 
the aqueous growth media (Figure 1.4) [45].   
 
Figure 1.4: Schematic of the macroscale experimental set up for the testing of the SP BE.  
Electric fields applied across the two electrodes have been shown to increase biofilm 
treatment efficacy as well as create a gradient of antibiotics within the experimental 
cuvette [8, 45]. 
 
The development of this potential treatment method using SP electric fields in 
conjunction with antibiotics is a focus of this work, where principle objectives include 
demonstrating this method at the microscale for potential clinical applications, while also 
reducing the voltages required for these electric fields to biocompatible limits, a 
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necessary step for the future use of this treatment method in patients.  Further discussion 
of this method, including its implementation, is discussed in Section 2.4 of this thesis.   
 
1.4.4 MEMS and Microfabrication 
Micro-electro-mechanical systems (MEMS) have been traditionally defined as the 
integration of mechanical microsystems with on-chip or external electronics for both 
sensing and actuating applications.  These technologies rely heavily upon the mature 
integrated circuit (IC) industry and the advantages of batch microfabrication in order to 
produce systems that are capable of diverse functions in ideally small, low power, and 
highly sensitive system architectures.  In recent decades, the field of MEMS has 
expanded beyond the realm of microscale mechanical systems to include the integration 
of biological, chemical, and optical components in order to increase the breadth of 
possibilities for these technologies [46].   
 The small size and batch fabrication capabilities of MEMS makes them ideal for a 
number of application areas.  Due to the capability of MEMS to be fabricated using 
techniques from the IC industry such as photolithography, thin-film deposition, etching, 
etc., these systems can often be produced more quickly and at a fraction of the cost of 
their macroscale counterparts [47].  As a result, numerous MEMS devices have reached 
production and are now fully integrated into larger electronic systems or exist as stand-
alone sensing devices.  Some of the most common include accelerometers, gyroscopes, 
micro-mirror arrays, microphones, microfluidics, and various sensors, with more devices 
reaching commercialization every year [48].   
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 The success and rapid growth of the MEMS field is largely attributable to the 
maturity of present IC fabrication capabilities, since many of the materials and processes 
implemented for the semiconductor industry are also used in the development and 
production of MEMS [48].  The majority of devices are constructed using materials 
native to the semiconductor field such as silicon and silicon compounds, other III-V 
group materials, and some metals, with bulk and surface micromachining enabling the 
realization of small-scale, three-dimensional features.  Bulk micromachining techniques, 
in which holes or trenches can be formed in an existing substrate, enable the full or 
partial release of MEMS devices, thereby allowing for physical movement of the device.  
Similarly, surface micromachining enables the creation of physical structures by first 
depositing materials onto a bulk substrate followed by patterning and etching of the 
material to create MEMS structures.  In addition to the use of CMOS-compatible 
materials, the development of new polymers and composites that are well-suited to these 
fabrication techniques enables the expansion of MEMS to other fields, where the 
requirements of specific applications have driven a need for materials that are 
biocompatible, flexible, or otherwise unique [48].   
 The advantages of using MEMS in lieu of macroscale devices extends beyond 
ease-of-fabrication and cost reduction, since many applications can benefit from the 
performance of devices manufactured at this scale.  While these benefits are broad and 
often specific to a particular use, they typically involve leveraging physical mechanics 
that scale well for various applications including: (1) the development of laminar flow at 
low Reynolds numbers, (2) increased surface-to-volume ratio for thermal transfer and 
surface reaction area, and (3) the non-linear scaling of mechanical strength compared to 
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generated inertial force [46].  Additionally, the ability of MEMS to integrate with 
present-day electronics and at a similar scale makes these systems preferable in many 
instances by providing simpler, more reliable, and more cost effective full-system 
packaging and assembly [49].   
 With these considerations in mind, MEMS and integrated microfluidics are ideal 
technologies for the biofilm growth, treatment, and monitoring system pursued in this 
work.  Microfluidics produced using high-throughput soft-lithography processes provide 
cost-effective, biocompatible alternatives to macroscale flow reactors that can provide 
enhanced control over assay parameters and conditions [12].  Furthermore, the materials 
used for microfluidic fabrication are chemically inert and therefore ideal for biofilm 
studies, where surfaces must serve as an attachment point for biofilm growth while 
avoiding extraneous chemical reactions that can affect the results of biofilm studies.  
Finally, the ease of integration of microfabricated structures and materials, such as the 
gold used for the electrodes integrated in the Micro-BOAT system, makes devices 
developed using such microtechnologies easily adaptable to different applications within 
a single system architecture.    This component approach to microfluidic system design, 
in which individual functionality is contained in subsystems such as micropumps, valves, 
mixers, channels, and detectors provides high system agility for adaptation to related 
applications in microbiology [12, 13].   
 
1.4.5 Bacterial Biofilm Measurement Methods  
 The following section provides a brief review of the literature with respect to 
methods for the measurement and characterization of bacterial biofilms in clinical and 
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biomedical applications.  While this summary is not intended to be all-inclusive, it 
provides a sufficient background and motivation for the development of the novel optical 
density method implemented through the Micro-BOAT platform presented here.   
 
1.4.5.1 Present-Day Industry Methods 
The system developed in this work for the growth, treatment, and monitoring of bacterial 
biofilms represents a new method of conducting studies related to bacteria and their 
infections, including those studies aimed at drug screening and development.  Currently, 
the majority of drug screening methods utilize macroscale devices and systems to 
perform assays that determine the effectiveness of prospective treatments on inhibiting or 
eradicating microbial growths.  Advanced industry methods utilize primarily automated 
systems to perform common screening techniques such as broth microdilution, antibiotic 
gradient, and disk diffusion studies on mature microbial cultures to determine the 
efficacy of various treatments as well as the minimal inhibitory concentration (MIC) of 
these drugs (Figure 1.5 and 1.6) [50, 51].  In addition to these microbiological methods, 
other immunoassays are frequently used to perform highly selective and sensitive studies 
by integrating methods such as ELISA (discussed subsequently in Section 1.4.5.2), 
fluoroimmunoassay (FIA) and time-resolved fluoroimmunoassay (TRFIA) with large-
scale capabilities, however, these methods are also limited in the types of molecules they 
can detect and therefore are not currently an all-encompassing method for antimicrobial 




Figure 1.5: A broth microdilution susceptibility panel (microtiter plate) containing 98 
reagent wells and a disposable tray inoculator [51].  Bacteria samples in suspension are 
treated with various concentrations of candidate drugs and each suspension tested using 
colony counting or spectroscopy to determine therapeutic efficacy.   
 
Figure 1.6: An Eclipse gradient diffusion testing plate featuring three candidate drugs on 
a single agar substrate.  The MIC of each agent is determined by the intersection of the 
organism growth with the measuring scale strip [51]. 
 
 While these various methods perform a similar function by enabling screening to 
determine a lead compound for a candidate drug, most current methods are limited by 
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their high cost, large size, and low throughput capabilities.  Moving forward, new 
methods of drug screening must utilize emerging technologies such as the micro/nano 
methods presented previously in order to take advantage of the benefits provided by 
devices at this scale [52].   
 
1.4.5.2 Macroscale Methods  
The majority of previous biofilm study mechanisms have utilized macroscale 
methods to determine biofilm viability, biomass, and overall structure for various 
biomedical, industrial, and environmental applications.  The majority of these studies 
were performed using macroscale flow reactors to culture biofilm samples with 
integrated, external detection methods [6].   
One of the most basic methods of biofilm quantification involves the counting of 
bacterial colonies, where bacteria are cultured on an agar plate and subsequently 
enumerated using microscopy and image analysis to determine their average density [54].  
Polymerase chain reaction (PCR) techniques are another standard method, which use the 
amplification of DNA segments to quantify the presence of target biological elements 
[55].  Fluorescence techniques provide an extremely accurate and simple method of 
biofilm detection by applying a fluorescent stain to a sample or, for greater precision, 
genetically engineering a bacteria strain to selectively express a fluorescent protein [56-
58].  Heyduk, et al. demonstrated the representative fluorescent immunosensor technique 
shown in Figure 1.7, in which nanometer length linkers modified with fluorochromes 
could participate in fluorescence resonance energy transfer (FRET) to increase 
sensitivity.  However, since this and similar approaches require a labeling method and 
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external microscopy equipment such as a confocal or fluorescence microscope for 
biofilm detection, it does not represent a high throughput or cost effective method of 
sensing, thus presenting a barrier to drug screening applications [7].  
 
Figure 1.7: Design of homogeneous biological immunosensors for pathogenic bacteria 
detection [57]. 
 
Similar to the FRET approach, considerable research has been directed towards 
the use of the Enzyme-Linked Immunosorbent Assay (ELISA) in laboratories to perform 
detection analyses on mixed cultures [59].  ELISA utilizes the specific binding of 
particular antibodies and antigens in combination with a fluorescent label to enable a 
specific and highly sensitive method for quantitative measurement of target antibodies or 
analytes in solution.  The method has seen vast use as a diagnostic tool in medical and 
other industrial fields and is also useful for chemical quality assurance due to its high 
sensitivity and selectivity [55].  A typical procedure for performing an ELISA analysis in 
a laboratory setting is provided in Figure 1.8 below.   
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Figure 1.8: Typical ELISA procedure: (1) A plate is coated with a suitable capture 
antibody (2) as sample is added any matching antigen is captured by the antibody (3) a 
suitable biotin labeled detection antibody binds to the antigen (4) a second conjugate 
antibody binds to the biotin labeled detection antibody (5) add a fluorescent label and 
read out [60]. 
 
Despite the highly selective and precise results provided by ELISA, it is rather arduous to 
perform, often requiring up to a full week for analysis, and often difficult to perform in 
lab-on-a-chip devices [57].  As a result, it has limited usefulness for high-throughput drug 
screening applications, lending to the development of new techniques for biofilm 
detection.   
 PCR, FRET, and ELISA techniques are commonly used in microbiology studies 
due to their high level of accuracy and precision, as well as their robustness as reliable 
quantification mechanisms.  The high cost, slow assay rates, large sample volumes, and 
expensive, labor intensive properties that define macroscale biofilm detection methods, 
however, motivates the development of similar techniques at the microscale in order to 
address the shortcomings of these technologies.   
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1.4.5.3 Microscale Methods  
Microscale methods leverage the technologies available for larger systems while 
taking advantage of capabilities only available in microscale and microfabricated devices.  
Some of these methods enable on-chip biofilm detection that is not possible in 
macroscale systems, while others adapt existing macroscale technologies to smaller 
environments.  By adapting macroscale technologies to microscale regimes, key 
advantages of micro/nano detection are leveraged including the use of small sample sizes, 
highly parallel throughput, tight control over environmental conditions, and inexpensive 
production through batch fabrication [11].   
Recently, the development of small-scale devices and microsystems for drug 
screening applications has received attention [52, 53].  These ‘lab-on-a-chip’ devices 
typically rely upon optical methods such as surface Plasmon resonance  (SPR) and 
fluorescence or electrochemical reactions on the sensor surface to detect microbial 
growth and treatment, which allows many measurements to be taken in situ.  In addition, 
the relatively low cost of these devices enabled by batch fabrication allows for 
microsystems that are specific to particular assay types and applications.   
 Fluorescence imaging methods have been adapted to integrate with microfluidic 
systems in a number of cases, allowing for increased control over the growth conditions 
of bacterial biofilms while taking advantage of a highly accurate and easily implemented 
optical detection method [61, 62].  Fluorescence microscopy systems of this type utilize 
fluorescent protein expression or cell staining methods to perform bacteria imaging and 
quantification of biofilm growth via cell colony counting or bacterial density.  Similarly, 
laser confocal microscopy systems enable in-depth analysis of localized biofilm 
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structures with respect to cell viability, surface roughness and morphology, and cell 
colony distribution within the polymeric ECM matrix.   
The device produced by Kim et al enables the testing of different bacterial signal 
concentrations on biofilms formed in microchambers by integrating a gradient mixer into 
a microfluidic flow cell [63].   
 
Figure 1.9: A microfluidic flow cell enabling gradient efficacy testing of eight 
concentrations of antibiotic simultaneously in a single device [63].   
 
The device produces results similar to those that could be obtained through traditional 
macroscale methods using lower reagent volumes and more paralleled experimentation, 
with analysis of biofilm growth being performed via confocal microscopy at select points 
in time.   
 In order to address the limitations of fluorescence detection methods at the 
microscale, the work conducted by Meyer et al utilizes a label-free method of detection 
based on the optical density properties of bacterial biofilms [6].  The system utilized 
microfluidic growth reactors on glass coverslip substrates such as those utilized in 
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fluorescence-based methods, with optical measurement performed by measuring changes 
in light transmittance through biofilms using COTS photodiodes.  The measurement 
technique provides an in situ method of overall biomass quantification that does not 
require a permanent fixture on the external equipment used in confocal and fluorescence 
methods, thereby allowing for highly paralleled biofilm testing at reduced cost.  While 
the use of discrete photodiodes in the microsystem limits the number of measurement 
points to a few select areas, a shortcoming considering the high variability of bacterial 
biofilm structures, the system can achieve real-time monitoring of changes in biofilm 
mass due to growth and treatment.   
For extensive analysis and detection at the molecular level, microscopic systems 
have also been integrated with ELISA methods in order to utilize specific fluorescent 
labels to detect the presence of target antibodies within a solution, such as bacterial 
biofilm cells.  While this and similar fluorescent microscopy-based methods are 
extremely accurate and provide precise information with regards to the development of 
bacterial biofilms, they require expensive and complex equipment for biofilm 
measurement and, without a permanent fixture upon the microscope stage to perform 
continuous in situ measurement, are limited explicitly to end-point measurements [6].    
 In order to enable continuous measurement of bacterial biofilm development 
without the use of optical measurement, electrochemical sensors have been developed 
that are able to detect biofilm growth with respect to both time and position within a 
microfluidic reactor [64-66].  Sensors of this type detect the presence of bacterial 
biofilms attaching to an exposed or passivated set of electrodes via changes in 
capacitance or impedance [67, 68].  While electrochemical biosensors provide continuous 
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detection and a relatively high level of precision, they require extensive characterization 
and calibration in order to produce reliable and meaningful measurements.  Output of the 
system is highly dependent upon the types of bacteria used and the aqueous media 
implemented, since each of these factors affects the electrical response of the system to 
changes in bacterial biofilm mass.  Finally, use of electrochemical detection methods 
requires significant signal processing as well as external equipment such as impedance 
spectrometers for precise signal analysis, thus adding undesirable complexity and 
overhead to the system architecture.   
 A final type of bacterial biofilm detection method utilizes surface acoustic waves 
(SAW) and shifts in propagating wave resonant frequency in order to determine changes 
in biofilm mass over a sensor area [69-71].  A set of interdigitated electrodes (IDT) on a 
planar piezoelectric substrate is fabricated to produce a known resonant frequency when 
the surface is unloaded.  As the mass of the material between the two electrodes changes, 
it results in a known resonant frequency shift that is detectable using a network analyzer 
or similar equipment designed to determine changes in signal resonance.   
 
Figure 1.10: A surface acoustic wave sensor passivated using atomic layer deposition 
(ALD) for bacterial biofilm monitoring and early detection [69]. 
 
Surface acoustic wave biosensors such as that produced by Kim et al for early biofilm 
detection are extremely accurate, with detection limits often below tens of pictograms 
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[69].  Widespread use of such a mechanism is limited, however, due to the complex 
nature of SAW sensor microfabrication and difficulties in utilizing SAW sensors for 
multiple and long-term experiments due to the fouling of sensing surfaces by developing 
bacterial biofilms.  As a result, SAW sensors and similar resonant devices are not 
typically used for commercial drug screening methods, which typically employ 
macroscale methods as described in the following section.   
 
1.4.6 Systems Engineering Principles in the Biomedical Field 
 In recent decades, systems engineering has begun to take hold as a freestanding 
engineering discipline motivated by a need to manage the design, development, 
operation, and integration of increasingly complex systems and networks.  While 
originally developed for use within large-scale corporations and projects such as military, 
government, and large-industry, recent years have made it increasingly evident that 
systems engineering principles are applicable, if not necessary, in a much broader 
spectrum of industries and fields [72].  For smaller scale industries and those that operate 
in less ideal research and development environments, systems engineering aids in the 
execution of design processes and daily operations that would otherwise face “imminent” 
failure if managed using less comprehensive methods.   
 The biomedical and pharmaceutical fields have begun to pursue the use of 
interdisciplinary research strategies in order to aid the development of new medical 
devices and antimicrobial treatments, as well as the operation of treatment facilities such 
as hospitals and clinics [72, 73].  In many of these applications, systems engineering lies 
at the heart of efforts to control development and system operation to ensure that 
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requirements are continuously met and safety is maintained.  As a case in point, in 2010 
the FDA initiated a requirement that infusion pumps for the intravenous delivery of drugs 
(i.e., insulin) must perform an assurance case in order to ensure patient safety even in the 
event of device malfunction or operator error [74].  Such assurance cases derive directly 
from systems engineering principles and are closely linked to the requirements and 
traceability matrices that guide principle design cycles to ensure proper device 
functionality.  Similarly, medical physicians and treatment facility analysts are now 
looking at the capabilities of adaptive systems engineering and similar principles to 
address inefficiencies and streamline medical care with respect to both patient flow and 
treatment efficacy [72, 75].   
 Looking forward, considerable encouragement has been set forth for the 
integration of systems engineering and related fields with microbiology in order to create 
a unified effort towards the development of new antimicrobial agents [15, 76].  
Integration at multiple levels of complexity and in diverse application areas has been 
suggested, including the fragmentation of microbiological processes to enable model-
based system engineering of biological systems and the use of control system theory to 
direct biological processes and treatments.  Overall, these efforts aim to enable 
biomedical scientists and engineers to develop treatments or devices that directly and 
acutely address requirements in order to ensure efficacy while limiting potentially 
negative emergent responses.  Thus, the use of systems engineering principles in the 
design of biomedical devices, such as those developed here for drug screening or 
bacterial biofilm monitoring applications, can direct system development to achieve a 
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more effective final product than is achievable by approaching the problem from biology 
or engineering perspectives alone [15].   
 
1.5 Thesis Organization 
 This thesis will be organized according to the following outline.  Following 
Chapter 1, which has provided the background and motivation of this work, Chapter 2 
discusses design considerations driving the development of the integrated Micro-BOAT 
system.  Specifically, this will present considerations towards the choice of optical 
detection and growth chamber methods, as well as systems engineering requirement and 
integration analyses that aid in the full enablement of the integrated microsystem.  In 
addition to providing design concerns pertinent to the development of the device, 
parameters relevant to the use of the SP BE treatment are also discussed.  Chapter 3 will 
provide the overall system design and fabrication with respect to the microfluidic biofilm 
growth chambers, optical density detection mechanism, and components required to 
generate the SP BE.  Assembly of the complete Micro-BOAT system will also be 
explored in this chapter.  Chapter 4 will investigate the performance of the Micro-BOAT 
by providing testing and results.  These results will investigate the performance of the 
system in terms of its ability to accurately and definitively detect the growth and 
movement of molecules within the microfluidic growth chamber, as well as its 
capabilities for biofilm treatment screening applications.  Finally, the integration of a 
novel bioelectric effect for biofilm treatment will be presented and its relative efficacy 
evaluated using the Micro-BOAT as a testing instrument.  An extensive discussion of 
these results will be presented at the conclusion of this chapter, evaluating the overall 
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performance of the Micro-BOAT as a tool for biofilm monitoring and drug screening 
applications, as well as determining areas of difficulty and possible improvement in the 
device design and implementation.  Finally, Chapter 5 will provide a summary of the 
research performed and presented in this thesis.  Future work will be presented, followed 
by an analysis of the potential impacts and benefits of this research, leading to a final 
conclusion.  Supplemental information, including signal acquisition programming and 


















Chapter 2: Systems Engineering of Experimental Biomedical Systems 
 Recent work in the area of systems engineering has made a discipline-wide thrust 
in the areas of systems biology and biomedical sciences, presenting the advantages of 
systems engineering principles and model based systems engineering (MBSE) in the 
development of biomedical devices and models for biological processes [8, 10, 15, 72, 
74].  A similar thrust has occurred in microfabrication fields, including MEMS, where 
systems engineering and MBSE have earned notoriety through the development of very-
large-scale integration (VLSI) design [77].  In both fields, there has been a growing need 
for the use of systems engineering in order to manage the increasing levels of complexity 
associated with systems such as that developed in this work [8, 10, 78-80].   
System design and validation is performed in this research using the high level 
descriptive modeling language SysML as well as several application-specific software 
packages to conduct low-level analysis of system component functionality. System-level 
design using SysML is performed using activity diagrams, state machine diagrams, 
sequence diagrams, use-case analysis, case diagrams, and requirements analysis in order 
to obtain a full understanding of the system functionality, structure, and control prior to 
the fabrication of system components for the final device.      
In order to enable the development of not only the system developed in this work, 
but the streamlined development of biomedical devices aimed at experimental 
applications on a broader scale, a principle focus of this work targets the development of 
a systems-driven design platform for experimental biomedical systems.  This platform 
provides a framework for the design of biomedical devices that is not currently available 
for devices in this regime, where the integration of biological systems and traditional 
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engineering device systems poses a number of unique challenges that must be addressed.  
Specifically, current systems engineering methods for the design of device systems 
cannot capture the stochastic and complex properties of biological systems, leaving 
developers in this regime to attempt to approximate these stochastic properties by 
integrating them into more complex requirements and approximations of potential 
biological system variance.   
 Here, a platform architecture is designed and proposed that attempts to bridge the 
gap between traditional engineering domains and biological domains by providing a 
method of formal system design that integrates the complexity of biological systems with 
the design of devices for target biomedical applications.  By providing such a means 
through a systems approach, an interface is created that enables both biologists and 
engineers to integrate requirements and system functionality in a single paradigm, thus 
ensuring validation and verification of the resulting system and increasing the efficiency 
of biomedical device development.  In the remainder of this thesis, the presented 
paradigm is implemented in order to demonstrate its utility for the development 
biomedical devices, with the microfluidic biofilm observation, analysis, and treatment 
platform providing a prime example.    
 
2.1 Systems Engineering as an Integration Tool 
 As described, the design of systems for biomedical applications, and specifically 
experimental biomedical applications, is complicated by the variant nature of the 
biological systems that play an integral role in the function of the overall system [8].  The 
growth of living organisms is dependent upon a large number of factors unique to each 
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system, typically driving a same set of biological system inputs to produce a stochastic 
set of system outputs, and making the design, validation, and verification of biomedical 
devices exceedingly difficult.  In designing experimental biomedical devices, the 
integration of both biological and device engineering domains is a necessity in designing 
systems that properly address system requirements, posing a current hindrance to the 
design of these devices, as the complex nature of biological systems limits their extensive 
understanding solely to biologists and clinicians well-versed in their respective fields.   
 To address this knowledge discontent, design techniques must implement a 
method enabling validation and verification of system performance in the context of these 
highly stochastic biological elements, thereby assimilating biological and engineering 
domains and enabling efficient device design [8].  Drawing upon the capabilities of 
systems engineering tools to model systems in the design phase, the development of a 
platform for engineering experimental biomedical systems is a large step towards 
producing more effective biomedical systems.  Figure 2.1 presents the method by which 
these platforms allow for the integration of biological and engineering domains, and 
forms the basis of the systems engineering design paradigm developed in this work.  
Here, the biological and engineering domains are pictured as separate regimes, i.e., the 
top and bottom halves of Figure 2.1.  The requirements of a specific application, such as 
functional, performance, interface, and testing requirements, are provided by those 
operating in the biological domain, in addition to models relevant to the application, such 
as models of the behavior or structure of the biological system.  The existence of 
mathematical models of biological systems enables the integration of such models within 
a description of the overall system, providing, from a system perspective, capabilities for 
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full architecture engineering.  Coincidently, the engineering domain proposes libraries of 
design options and components defining the architecture space.  By integrating these two 
domains within a single platform interface, the entirety of the explorable design space is 
accessible to enable the concrete design of a biomedical device system addressing the 
requirements of the biological application.   
 
Figure 2.1: Conceptual diagram presenting the integration of biological and engineering 
domains at a platform level, designed and developed in this work for the acquisition of 
system architectures that successfully satisfy design requirements unique to the 
integration of these two domains.    
 
In order to capitalize upon the added capabilities of such a technique, two key 
tenets of this work are that (1) methods to succinctly model a breadth of biological 
systems must be developed, and (2) these models must be able to integrate with system-
level models capable of describing the performance of the entire engineering system.  
Recent work in the area of systems engineering has made a discipline-wide thrust in the 
areas of systems biology and biomedical sciences, presenting the advantages of systems 
engineering principles and model based systems engineering (MBSE) in the development 
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of biomedical devices and models for biological processes [8, 10, 15, 72, 74].  A similar 
thrust has occurred in microfabrication fields, including MEMS, where systems 
engineering and MBSE have earned notoriety through the development of very-large-
scale integration (VLSI) design [77].  In both fields, there has been a growing need for 
the use of systems engineering in order to manage the increasing levels of complexity 
associated with systems such as that developed in this work [8, 10, 78-80].  Through 
these thrusts, both points (1) and (2) mentioned above are satisfied, and the system 
paradigm is achievable through the interface of these modeling mechanisms.    
Functionally, the platform presented in Figure 2.1 can be implemented through 
hierarchies of modeling paradigms that, overall, enable the integration of the biological 
and device engineering domains, which is then accessible at a higher level through the 
use of standardized systems engineering tools, such as the SysML or UML languages.  
System-level design using SysML is performed using activity diagrams, state machine 
diagrams, sequence diagrams, use-case analysis, case diagrams, and requirements 
analysis in order to obtain a full understanding of the system functionality, structure, and 
control prior to the fabrication of system components for the final device.  Using these 
languages as a framework on which to integrate lower level models of device 
components and subsystems in addition to biological models, a full-system model is 
realized that can fully describe the functionality of the experimental biomedical system 
under development.  This implementation can be visualized as in Figure 2.2, presented 
below, in which the design spaces of Figure 2.1 are mapped to a modeling regime, 
thereby displaying the integration of different modeling techniques to achieve a complete 




Figure 2.2: Abstraction as a tool for the design of biomedical systems.  The design 
paradigm, or “platform,” establishes application goals and scenarios that are modeled 
at a high level, while the design space is explored through detailed simulations of specific 
system components [15]. 
 
2.2 Platform for Designing Experimental Biomedical Devices  
 The developed platform for the system-level design of experimental biomedical 
systems can be divided into two high-level areas of system architecture, namely, an 
experimental process or functionality related to the device system, and the physical 
design and implementation of the device system.  As implemented, the systems 
engineering paradigm recognizes a typical experimental process utilizing a device 
architecture is shown in Figure 2.3.  The researcher or clinician begins with a hypothesis 
about their subject that, for example, may be founded in prior data of biological systems 
or patient symptoms [81].  For a medical researcher or systems biologist, this hypothesis 
may involve a parameter or process that the experiment is intended to verify.  Examples 
commonly include a metabolic process, the effects of a compound on a biological system 
(e.g., candidate drug), or verification of the unique characteristics of a particular 
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organism.  For the clinician, a hypothesis may involve a patient diagnosis or prognosis, or 
may be geared towards determining an effective treatment for a patient’s verified medical 
condition.  With this hypothesis in place, an experiment is begun under ideally controlled 
conditions.  At the conclusion of the established assay, the researcher or clinician inspects 
the outcome to determine if the test was successful or if alterations or repetition of the 
experiment is required.  Due to the highly stochastic nature of biological systems, such a 
feedback process is common in order to verify experimental results.   
 
Figure 2.3: Activity diagram presenting the system-level functionality of biomedical 
devices during experimental procedures.  Beginning with a set of predetermined 
experimental conditions, continuous monitoring of the biological system enables 
feedback in the system operation that can optimize experiments as well as detect errors 
occurring in situ [15]. 
 
The goal of the design engineer is to develop device systems that can aid in reducing the 
number of iterations needed to achieve a required level of confidence in the result.  This 
is especially important in clinical applications, due to the patient discomfort often 
associated with invasive testing (e.g., prick tests to determine skin allergies).  Similarly, 
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current medical research often utilizes high cost, low throughput methods of testing, 
giving strong motivation for the development of methods to limit the number of iterations 
needed to verify an experiment.   
Coincident with the structure for system performance, the physical structure of 
biomedical devices can be approximated using a high level architecture that is useful for 
a variety of applications.  While the structure of such devices for experimental 
applications is diverse and typically suited to the needs of the particular application, most 
systems can be abstracted to the system architecture shown in Figure 2.4.   
 
Figure 2.4:  Implementation of the platform for experimental biomedical devices, 
utilizing a device architecture in which system inputs affect integrated biological and 
physical system modeling structures.  The resultant of these interactions is detected by a 
physically implemented sensory network, which acts as a transducer to detect the 
biological system output, which can then be recorded as a set of responses (Res. 1-N).   
 
System inputs are typically comprised of a number of different domains, including 
environmental conditions and actuation or application conditions (i.e., what is done to the 
biological system during the experiment).  Depending upon the requirements of the assay, 
the physical device system can take any number of forms but will typically have three 
distinct structural elements including: (1) a way to contain or integrate with the biological 
system or sample, (2) a way to control experimental conditions, and (3) a way to integrate 
with a sensor network for detection.  The sensing mechanisms utilized for experimental 
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devices also vary depending upon the application, though they typically aim to optimize a 
tradeoff between minimal invasiveness and achieving the required detection limit and 
sensitivity of the application.  The cumulative effect of the physical system’s interactions 
with the biological element results in a set of potential experimental results, each having 
a unique probability of occurrence.  These probabilities are dependent upon the stochastic 
biological system, providing at the simulation level a range of statistically relevant 
outcomes that can be used to confirm experimental results.  Figure 2.5 provides a high-
level implementation of the system elements and their interactions at the component and 
subcomponent levels.   
 
Figure 2.5: State machine diagram presenting the functional dependencies of biomedical 
testing devices.  Based on the set of system interdependencies between simulations/initial 
conditions, physical device systems, and integrated data processors, an optimized system 
is realized for this research work [15].   
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Most biomedical devices are constructed through a similar architecture, providing strong 
support for the development of the generalized platforms for experimental device 
engineering presented here.  The platform exhibits a flexible structure that can be adapted 
to numerous applications in the biomedical field, thus expanding the scope of the 
developed platform.  The development of libraries of components to represent physical 
systems (e.g., through finite element modeling tools, and/or subsystems modeled through 
SysML or UML) and sensory network elements (e.g., using similar tools as for the 
physical device systems) aids in the efficient development of new devices and the 
adaptation of existing devices to new application areas.  Additionally, the formal platform 
of such an implementation is capable of integrating such libraries with models of 
stochastic biological components, enabling full-system modeling that can effectively aid 
efficient and proper design, validation, and verification of biomedical systems.  The 
implementation of such a platform using existing systems languages like UML and 
SysML as presented here, takes advantage of the mature properties of these tools, where 
implementing extensions to other modeling domains is a well-established practice.  As 
explained in the following section, the use of Markov Chain modeling and Hidden 
Markov Models is ideal for such an application, and is explored in this work as a 
preliminary study of the capabilities of the presented paradigm for the design and 
modeling of biomedical device systems.    
 
2.3 Biological System Modeling via Markov Chains 
 Markov Chains and Hidden Markov Models provide a method of modeling 
probabilistic systems with finite states, making them ideal for the modeling of biological 
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systems, including numerous common biological systems relevant for biomedical devices 
[82].  While this method has existed for over a century, only recently has it begun to see 
significant use in engineering applications to understand the development of systems over 
time.  A Markov Chain model can be easily visualized as a set of states, each with a 
probability of propagation to a future state.  Figure 2.6 shows how a simple Markov 
Chain may be easily visualized.   
 
Figure 2.6: An example Markov Chain model featuring four finite system states (A-D), 
with an example set of propagation paths and respective probabilities (aXY), where the 
probability is expressed as the probability of propagating from state X to state Y in a 
given step.  For any system state, the sum of the propagation probabilities to other states 
must be equal to 1.0, including the odds that the system states at the same system state, 
such as in propagation probability aDD. 
 
Each state of the Markov Chain model represents a physical system state, with arrows 
showing the probability (aXY) of propagation from state X to state Y in one time step.  
The sum of all propagation probabilities from each state must sum to 1.0, with feedback 
or steady-state operation between states also being possible.  Additionally, segmentation 
and hierarchical Markov Chain models are also possible, where the probabilities of a 
state’s propagation may be dependent upon the current state of a separate, but related, 
Markov Chain.  For the application discussed here, this property is leveraged in order to 
build intrinsic hierarchies of biological system complexity, thus allowing for full system 
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analysis from both high and low levels.  Additionally, Markov Chain models offer an 
easily scalable method of modeling biological systems (in lieu of traditional systems of 
partial differential equations) and enable the modeling of highly complex systems in a 
manner that is intuitive, adaptable, and quick to implement or alter in software [82].   
Hidden Markov Models are an extension of the Markov Chain concept, where the 
Markov Chain or network of interacting Markov Chains are developed based on observed 
real-world performance.  Behavior of a system, be it discrete in nature or a continuous 
spectrum, is tracked and documented, and then a Markov Model is developed to fit this 
system performance.  This model then enables further analysis or prediction of future 
system functionality [82].  The emergent properties of these models makes them 
“hidden” to the model developer, since it is not initially clear how system states may be 
related or with what probabilities the system may fluctuate between states.  With respect 
to the development of the platform presented here for the systematic design of biomedical 
devices, Hidden Markov Models play a valuable role by enabling researchers and 
developers to empirically develop biological models of systems in instances where these 
models do not initially exist, thus expanding a library of available (i.e., “stock”) 
biological models.   
 
2.4 Implemented Platform for Biomedical Device Development 
 By combining the modeling mechanisms available for physical engineering 
systems with the Markov techniques presented for biological systems, this work presents 
a comprehensive platform realized for the full system design of experimental biomedical 
devices.  Borrowing from the high-level system architecture in Figures 2.4 and 2.5, this 
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framework platform creates a union of the biological and engineering domains that 
enables the simulation of a full biomedical system.  Figure 2.7 showcases how such a 
union is achieved in this work, where the biological element is modeled as a component 
in the system architecture.   
 
Figure 2.7: Implementation of the developed platform for the engineering of experimental 
biomedical device systems.  The stochastic biological element is inserted into a functional 
model of the device system, enabling full system modeling.  Hierarchical structures of 
Markov Chains enable varying levels of abstraction to be used when modeling the 
biological element of the full biomedical device system. 
 
Modeling of the full system architecture is achieved using established systems modeling 
platforms, such as UML or SysML, as many of these tools have reached a level of 
maturity to support extensions to other languages and models.  In order to utilize the 
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platform for overall engineering of the biomedical system, the implementation process 
follows a straightforward path as follows: 
1. Gather relevant data of the biological system at a level of abstraction 
coincident with the application requirements.  This data will be used to 
formulate a Markov model of the biological system component. 
2. Formulate a Markov model describing the biological component.  An 
iterative process is often used to achieve convergence of such a model, as 
well as to define the appropriate segmentation of finite states for continuous 
systems [82, 83].  
3. Represent the validated Markov model using a tool capable of integrating 
with the physical system model.  This biological element will exist as an 
extension from the modeling platform used to define the larger device 
system.   
4. Design the proposed physical device components and how these components 
relate using the modeling platform named in (3) (i.e., SysML or UML).  An 
additional component should also be represented in the system model that 
will extend to the biological component.   
5. Perform simulation, validation, and verification of the complete system 
model.  The results of these analyses will provide a means of redesign and 
device optimization for the particular experimental application.   
The outputs generated from this system analysis provide a range of potential 
experimental outputs based on the operation of the physical system and the development 
of the stochastic biological system.  The value of obtaining such a resultant set is 
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paramount to the design engineer, as it allows them to directly address real-world 
concerns that are not otherwise visible in the design phase.  In the prototyping phase of 
device development and beyond, this same analysis can be used to verify proper device 
operation, to confirm the results of experiments, and to detect and avoid undesirable 
system performance.  Such analyses are currently difficult and exceedingly time-
consuming using established methods, giving a platform for experimental biomedical 
device development considerable value to the field.   
 Using the established platform for the design of biomedical devices, the Micro-
BOAT platform is analyzed in light of both physical system and biological system 
considerations in order to optimize the system for the proposed application of performing 
in situ growth, monitoring, and treatment of bacterial biofilms in a microfluidic 
environment.  As presented in the following sections, these two areas are pursued 
independently in order to establish the component functionality of the system, evaluate 
the efficacy of Markov techniques for the approximation and prediction of biological 
systems, and determine the readiness with which the two domains integrate for full 








Chapter 3: Design Considerations and System-Level Engineering 
 In the design of integrated systems involving multiple component types and 
interactions between various physical and biological modules, a system-level approach to 
the design of individual components is needed in order to ensure a properly functioning 
end product that supports the requirements of the application.  For the biomedical Micro-
BOAT device in this work, a systems engineering “platform”, or design paradigm, is 
implemented as a flexible methodology that can be applied uniformly to any number of 
biomedical devices.  In the design of the Micro-BOAT, subsystem components and their 
interactions are taken into consideration as a fundamental step in the development 
process.  The following sections in this chapter outline such considerations and the 
figures of merit that support the design of each component, as well as how these factors 
drive not only the design of the system but also use of the system for the demonstration 
of the SP BE as a potential clinical method for biofilm treatment.   
 
3.1 Design Considerations 
 The key focus of this work is the development of a device for the growth, 
monitoring, and on-chip treatment of bacterial biofilms that can be used as a tool for drug 
screening and development applications.  To most effectively address this system 
functionality, a number of design factors and options for the components were 
considered.  Overall, the areas of consideration for the system design can be placed into 
two separate, yet interdependent, categories: (1) methods of effectively monitoring 
biofilms and (2) methods of enabling on-chip biofilm growth and development.  
Additional consideration is also given to the use and implementation of the SP BE 
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enhanced biofilm treatment method tested in this work.  An analysis of these alternatives 
resulted in the presented integrated Micro-BOAT system consisting of a microfluidic 
biofilm growth chamber with an optical density (OD) detection method achieved via 
linear array charge-coupled devices (CCD).   
 In determining the monitoring schema that best matches the application presented 
here, it was established that the preferred method would integrate well with the selected 
biofilm growth reactor architecture while also satisfying functionality requirements 
unique to the drug screening tool.  In order to address the limitations of current biofilm 
measurement technologies, the selected sensing method should be capable of continuous, 
in situ monitoring of biofilm growth, development, and treatment with minimal external 
equipment.  Furthermore, in unison with the requirements of the biofilm growth reactor 
explained subsequently, the ideal monitoring solution should be capable of parallel 
implementation on a single chip in order to allow for biofilm detection in multiple 
experiments simultaneously.  The sensing mechanism should be non-invasive to the 
furthest extent possible in order to emulate realistic biofilm growth and treatment in a 
laboratory setting, while also being cost effective to implement, allowing for large-scale 
drug screening operations.   
In combination with the requirements of the biofilm monitoring mechanism, 
several factors were of principal importance in regards to the reactors for bacterial 
biofilm growth and development.  Due to the high cost of candidate drugs in low 
production quantities, it is preferred that the biofilm growth chamber utilize small reagent 
volumes in order to limit the costs associated with treatment efficacy experiments.  
Furthermore, the biofilm growth chamber must be biocompatible, meaning it is both non-
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toxic to the bacteria and non-reactive with other chemicals that may be used in biofilm 
experiments, such as chemical stains, growth media, or other biocides.  In order to enable 
realistic in vitro biofilm experiments that are representative of in vivo applications, the 
growth chamber must be capable of emulating conditions within the human body, 
including temperature (37 C) and pH.  Finally, in order to achieve high throughput 
testing, the developed biofilm growth reactor should be able to accommodate parallel 
bacterial biofilm growth and in situ monitoring by integrating with the chosen detection 
method.   
 The designed microsystem addresses device requirements by integrating a 
microfluidic growth chamber formed in the biocompatible silicone polydimethylsiloxane 
(PDMS) with CCD integrated circuit (IC) components for optical biofilm sensing [84, 
85].  The biofilm growth chamber can be fabricated on other biocompatible materials 
such as gold and Pyrex
TM
 while utilizing small reagent volumes on the orders of tens of 
microliters [86, 87].  By placing these microfluidic chambers on a transparent substrate, 
optical monitoring can be used to determine real-time changes in biofilm OD using CCD 
components to achieve a non-invasive method of biofilm measurement [14].  Based on 
these factors, the integration of these two mechanisms represents a system design space 
that is well suited to drug screening applications featuring bacterial biofilms and a 
potentially broad spectrum of candidate biofilm treatments.   
 
3.2 Measures of Effectiveness at the Micro-BOAT Device Level 
 The following sections analyze the various technologies and components utilized 
in the Micro-BOAT system in order to determine the optimal design parameters and use 
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of these components to satisfy the design requirements of the presented device.  Measures 
of effectiveness are analyzed at a low level via the performance metrics and governing 
equations that determine the physical operation of the integrated system. Specifically, 
these measures of effectiveness include (1) the measurement of biofilm optical density as 
a means of quantifying changes of biofilm mass, (2) the suitability of implementing CCD 
components in the Micro-BOAT to achieve biofilm OD measurement, (3) the design of 
the microfluidic biofilm growth reactor as a component in the Micro-BOAT system, and 
(4) the implementation of the SP BE within the developed device for the testing of 
enhanced bioelectric biofilm treatment.   
 
3.2.1 Optical Biofilm Density 
 Optical density has been shown as a viable metric of biofilm growth and 
development correlating to overall biofilm mass [88].  As biomass accrues, light incident 
upon the film is increasingly absorbed by bacterial cells and the extracellular matrix, 
resulting in a decrease in light intensity transmitted through the film.  The Beer-Lambert 
Law for light absorption in a material provides a method for correlating this absorbance 
to overall biomass, where the concentration of bacterial cells is proportional to light 
intensity reduction within fixed ranges of cell size and shape [14, 89].  The governing 
equations for these physical properties are provided in equations (1) – (3) below, which 
derive the biofilm optical density measurement.   







       (2) 
       (3) 
Here, T represents transmission percentage,  is the absorbance coefficient,  is the path 
length, A is absorbance in arbitrary absorption units (AU), I is light intensity, and Io is the 
initial reference light intensity.  While factors such as wavelength, light path type, and 
detection device are also relevant parameters for this measurement, these are considered 
in the coefficient values and quantity for the path length and are thus supported by this set 
of equations.   
 Investigations into the correlation between optical biofilm density and biofilm 
characteristics such as biomass, thickness, and morphology have been performed 
previously (Figure 3.1) [14, 88].   
 
 
Figure 3.1: Biofilm total organic carbon (TOC) concentrations have a linear correlation 
to measured biofilm OD [14].  Here, the line represents the best linear fit forced through 
the origin (R2 = 0.59).   
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Bakke et al demonstrated a linear relationship between biofilm mass and optical density 
for thin-film bacterial colonies on the order of 35 m.  While this linear relationship 
holds for bacterial biomass, the optical density measurement shows only limited 
correlation to biofilm thickness and morphology.  Thus, we can utilize the OD 
measurement method to quantify biofilms with respect to overall growth, while other 
measurement techniques may be better suited to investigating other structural 
characteristics.  In figure 3.2, below, biofilm thickness was shown to reach a steady state 
after approximately 100 hours of growth, while the optical density continued to increase 
for >200 additional hours.  This suggests that the biofilm did not achieve full maturity, 
signified by reaching a steady-state overall biofilm biomass, until this point in time, 
despite this suggestion by other measured parameters including biofilm thickness, 
substrate concentration, effluent TOC, and cell concentrations [14].   
The ability of optical density measurement to detect and quantify the development 
of bacterial biofilms beyond the capabilities of these traditional metrics provides strong 
support for the use of OD as a biofilm growth valuation.  Additionally, optical density 
measurement is preferential for biofilm studies for several other reasons including: (1) 
non-invasive biofilm detection (samples are taken without physical contact with the 
biofilm), (2) real-time, in situ measurement with minimal overhead in terms of 
equipment, complexity, and time required to perform measurements, (3) low internal 




Figure 3.2: Biofilm optical density and relation to average biofilm thickness. (a) Biofilm 
OD increases for approximately 300 hours before reaching steady state. (b) Steady state 
biofilm thickness is achieved after only approximately 100 hours of growth [14]. 
 
The frequency of light used to measure optical density can be tuned to address the 
sensitivity of a specific sensor device or to determine absorbance of specific target 
molecules within materials or cells.  For typical OD applications, the selection of a single 
light frequency to match the specified photodetector can increase measurement 
sensitivity, while the scanning of multiple frequencies can provide insight with respect to 
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low-level molecules within material or biological structures.  Bacterial biofilms such as 
those examined in this work typically display broad-spectrum OD changes due to 
reflection from large components in the biofilm matrix, such as bacterial cells, and 
therefore do not show preferential absorption or reflection at specific wavelengths.  As a 
result, OD measurements can be taken using many light frequencies while displaying 
similar biofilm absorbance, therefore motivating the chosen OD measurement frequency 
to be tuned to the photodetector device in order to optimize the sensitivity of the 
application.   
For these reasons, the use of optical biofilm density measurement is a preferred 
method of biofilm monitoring and well suited for the prescribed use.  The mechanism can 
be readily adapted to drug screening instruments such as that presented in this work and 
provides a means of non-invasive, sensitive, and highly scalable biofilm growth detection 
which is well suited for real-time detection applications.  
 
3.2.2 Optical Density Monitoring via Charge-Coupled Devices 
Biofilm optical density monitoring is typically achieved by transmitting light 
through the biofilm reactor normal to the substratum/biofilm interface (Figure 3.3).  
When grown on a transparent substrate and in a reactor that can transmit light with little 
absorption or reflection, biofilm OD is detected using a photodetector placed on the 
backside of the reactor opposite a light source.  A baseline measurement removes 
background absorbance by the biofilm growth reactor material and fluid within the 
reactor.  Increasing bacterial density on the substrate results in the attenuation of light 
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intensity transmitted through the device, which can then be converted to a net change in 
OD according to equation (2).   
 
Figure 3.3: Optical density detection of biofilms in fluidic reactors. (a) A baseline 
measurement removes the absorbance properties of the reactor materials and fluid. (b-c) 
As bacterial biofilm density increases, optical density also increases according to 
equations (1-3). 
 
 Due to the highly stochastic nature of biofilm growth, in which bacterial density 
and morphology often vary drastically across a single biofilm or substrate, it is desirable 
to have localized measurements throughout the biofilm structure in order to determine 
average and spatiotemporal changes in optical density.  An array of photodetectors 
positioned on the backside of the reactor can enable this detection.  While light scattering 
and reflection due to the irregular biofilm surface limits the spatial resolution of such 
detection, knowledge of an average biofilm OD can greatly enhance the accuracy of 
experimental results, while an understanding of spatial biofilm distribution provides 
further insight into the developments of the film under applied conditions.   
 In order to leverage the advantages of operating at the microscale, this work 
implements a compact linear array charge-coupled device (CCD) to enable both average 
and spatiotemporal biofilm monitoring along the full length of a growth reactor.  The 
device (Texas Advanced Optoelectronic Solutions TAOS-TSL202R) features a 128x1 
linear array of photopixels integrated into a sealed IC package [90].  Each pixel measures 
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120 m (H) by 70 m (W) with 55 m pixel-to-pixel spacing for an overall linear array 
length of 1.6 cm.  The IC package is a standard through-hole component measuring 19 
mm (L) by 11 mm (W) and was chosen due to its simplicity of operation and ease-of-
implementation on a standard printed circuit board (PCB).   
 The principle of operation of the device is as follows: as light energy impinges 
upon the pixels of the CCD, photocurrent is generated which is integrated by the active 
circuitry located on-chip and stored in a sampling capacitor that corresponds to each 
pixel.  The amount of charge accumulated on each pixel’s capacitor is directly 
proportional to the light intensity and integration time according to equation (4), where 
Vout is the analog voltage output of that pixel, Vdrk is the analog voltage for the dark 
condition, Re is the device responsivity for a particular wavelength of light, Ee is the 




and tint is the integration time in seconds.  The linear 
response of this output to irradiance is critical to enable biofilm optical density 
measurement with limited calibration of the device.  Since Vdrk approaches 0 V while the 
device responsivity and integration time are constant during operation of the system, we 
can directly derive the relationship between optical density and CCD pixel output voltage 
according to the following:   
        (4) 
      (5) 
      (6) 
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Substituting equation (5) into equation (6), one finds a final representation for the overall 
relationship between the analog output voltages and absorbance.  
      (7) 
      (8) 
 
Thus, optical density measurements can be obtained directly using equation (6).  
Operation of the device is achieved using only a DC rail voltage, a timing clock and a 
serial-input (SI) that triggers the discharge of the pixels for signal readout.   
 
Figure 3.4: Timing diagram of the TSL202R charge-coupled device.  A serial-input bit 
during a rising edge clock pulse (CLK) triggers data readout from the 128 pixels, with 
each clock pulse shifting the pixel being read.  A 129th clock pulse returns the output to a 
high-impedance state [90].   
 
Maximum device responsivity is achieved at a visible red wavelength of approximately 
680 nm, which is the wavelength chosen for optical density measurement since biofilm 
absorption is broad spectrum and thus non-sensitive to the frequency selected.   
 The selected device is optimal for the application of drug screening due to its 
established performance characteristics and steady operation, with reported noise levels 
of 1 mVrms.  Implementation of the device is readily achieved due to the on-chip 
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circuitry, which supports most data storage and readout functions.  The small size of the 
device is ideal for the adaptation of drug screening processes to the microscale, since the 
device can integrate easily with a microfluidic or other small-scale growth reactors for 
biofilm optical density monitoring.  Finally, the linear output response of the device 
makes it ideal for measuring biofilm optical density since recorded voltages can be 
translated directly to optical density according to equation (6) with limited calibration.   
 
3.2.3 Microfluidic Biofilm Growth Flow Cell  
 A microfluidic growth reactor has been designed for this work that addresses the 
needs of the application to provide a chamber for the biocompatible growth, treatment, 
and monitoring of bacteria biofilms.  In order to meet these requirements, several 
considerations determine the design of the microfluidic channels used in the Micro-
BOAT system.  The dimensions and materials used to structure the microfluidic channel 
must meet the needs of OD detection, while being of an adequate size to support the 
growth and treatment of clinically relevant biofilms.  By optimizing the microfluidic 
component of the overall system, an end product device is achieved that is functional for 
drug screening and biological studies of bacterial films.   
 The microfluidic biofilm growth flow cell developed for this work is comprised of 
a 100µm deep, 2000µm wide, and 1.75cm long microfluidic channel formed in PDMS on 
a Pyrex
TM
 substrate.  PDMS was chosen as a fabrication material due to its 
biocompatibility for biological experiments, transparency, ease of fabrication and 
replication (see Chapter 3: Device Fabrication), and low cost as a silicone polymer.  A 
Pyrex
TM
 substate was chosen for many of these same advantages, in addition to its 
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relative thinness (500µm) in comparison to other viable options, such as a glass 
microscope slide (>0.8mm).  The footprint of the microfluidic chamber was optimized to 
allow for visual alignment of the channel to the CCD photopixel array.  Since 
misalignment of the pixel array and microchannel would result in unreliable device 
operation in which changes in biofilm OD are missed or skewed, the microfluidic channel 
is sized to allow for sufficient overlap of the microfluidic chamber over the linear pixel 
array.  Doing so considerably mitigates the chances that developments in biofilm OD 
within the channel will proceed undetected by the CCD pixel array.  Figure 3.5 below 
provides a top-down view of the microfluidic channel design used for the Micro-BOAT 
system.  The tapered portions of the channel leading to the 2mm diameter inlet and outlet, 
used to provide a fluid flow source through the top of the PDMS slab, are not included in 
the dimensions of the microfluidic chamber.   
Figure 3.5: Top-down schematic of the microfluidic channel used for biofilm growth and 
treatment in the Micro-BOAT system, also showing the positioning of the CCD pixel 
array with respect to the channel.  Proper alignment of the channel to the CCD device 
ensures effective biofilm sensing. 
 
Total chamber volume is designed to support bacterial biofilms and is supported by 
previous research that utilizes microfluidic channels as biofilm growth reactors.  These 
chambers typically range in depth from 20µm to 250µm, with total growth reactor 
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volumes typically ranging from several picoliters to several microliters [6, 63, 65, 87, 91, 
92].  Dimensions of the channels used in the Micro-BOAT system provide a 200nm
2
 
cross-sectional area and a total chamber volume of 3.5µL, placing it on par with other 
microfluidic growth reactors.  At this scale, channel clogging due to biofouling is rarely 
encountered and the size of the inlets and outlets of the microfluidic devices are large 
enough to support commercially available fluidic interfaces such as connectors and 
capillaries.   
 Fluid flow within the microfluidic device can be characterized using standard 
equations for rectangular fluidic channels at small scales and low Reynolds numbers [93].  
Flows at this scale can be described using the equations below in terms of their average 
and maximum flow velocities, flow-induced shear stress, and Reynolds number.     
      (9) 
      (10) 
      (11) 
Here, and UMax represent the mean and maximum flow velocities, respectively, Q is the 
volumetric flow rate, W the width of the channel and h the height of the channel.  
represents the flow-induced shear stress in the channel,  the dynamic viscosity of the 
fluid,  the density of the fluid, Re the Reynolds number of the flow, and DH the 
hydraulic diameter of the channel.  For typical volumetric flow rates used in biofilm 
growth applications (less than 100µL/h), the fluid characteristics of water at 40ºC (used 



























geometry used in this device system, we can characterize the microfluidic device 
performance using the following plots.   
 
 
Figure 3.6: (a) Volumetric flow rate versus flow velocity for the microfluidic channel 
used in the developed Micro-BOAT. (b) Flow-induced shear stress increases as biofilm 
height increases in the 100µm tall microfluidic channel.  These values are characterized 
at 20µL/h, the volumetric flow rate typically used for device experiments (see Chapter 5). 
 
As seen above, the volumetric flow rate is directly proportional to the induced laminar 
flow velocity, allowing the rates of either to be tuned to achieve either environmentally 
relevant sheer velocities or to maximize new media flow to the developing biofilms.  
Additionally, sheer stress is found to vary inversely with h
2
, which encourages the use of 
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such tall channels as those used here in order to achieve increased biofilm thickness at the 
expense of larger device sizes and increased sample volumes (see section 1.4.1 for the 
effects of sheer stress on biofilm development).  Laminar flow is generally achieved for 
Reynolds numbers below Re = 1000.  For this system, the Reynolds number is on the 
order of 0.001 for most flow rates, making flows in this system dominated by diffusion 
effects rather than turbulence.  This characteristic enables greater control over the 
conditions of experiments within the microfluidic chamber.   
 
3.2.4 Bioelectric Effect for Biofilm Treatment 
 While much of this work focuses upon the development of a microsystem for 
drug screening applications, it is in many ways the use of this tool to conduct novel 
biofilm treatment studies that can express the full impact of this research.  Recent work in 
our research group has validated an enhanced bioelectric effect for bacterial biofilm 
treatment at the macroscale [94].  In order to demonstrate use of the integrated biofilm 
growth and treatment system presented here, experimental work in this research area 
aims to establish the effectiveness of this novel treatment in microscale applications.  The 
successful validation of this treatment has far-reaching consequences by providing a new 
and promising method of enhanced treatment of bacterial biofilms that do not involve the 
use of new or increased quantities of antibiotics.   
In this work, the efficacy of the superpositioned bioelectric effect described in 
section 1.4.3 is tested in a microscale system by integrating electrodes with the 
microfluidic channels in order to provide the electric fields necessary for bioelectric 
treatment.  Gold electrodes are fabricated upon the Pyrex
TM
 substrate of the microfluidic 
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channels in order to provide two functions simultaneously: (1) generate electric fields 
needed for the SP BE and (2) limit peripheral light from entering the charge-coupled 
device pixels, thereby limiting noise in the system.  The pattern used for these electrodes 
is shown in figure 3.7 and the fabrication process is presented in the next chapter.   
 
Figure 3.7: Pattern of the microfabricated gold electrodes used in the Micro-BOAT.  The 
electrodes generate an electric field perpendicular to the direction of flow in the 
microfluidic channels and the rectangular spacing between the electrodes enables the 
limiting of peripheral light from polluting the changes in light transmission to the CCD 
devices due to changes in biofilm optical density.   
 
Intensity of the electric field used in this work was characterized to operate within 
biocompatible limits while simultaneously avoiding hydrolysis of the aqueous media that 
occurs above a threshold voltage potential [95].  The frequency of the AC component of 
the SP electric field was selected based on previous literature in order to demonstrate 
maximum efficacy of biofilm treatment [45].  Based upon these factors and previous 
work in the MEMS Sensors and Actuators Lab, the SP electric field is composed of a 
1.25V/cm sinusoidal signal at 10MHz with a 1.25V/cm DC offset.  For an electrode 
spacing of 2mm, as we have in this system, this equates to an applied AC peak-peak 
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voltage and DC offset of 0.25V for both parameters.  This electric field effectively avoids 
the hydrolysis potential of the system which is found to occur at 2.0V/cm or 0.8V 
applied.  For this structure geometry, in which electrodes are evenly spaced along the full 
length of the microfluidic channel, the generated electric field is perpendicularly in-plane 
to the direction of fluid flow in the channel, with the resultant electrophoretic force being 
orthogonally out-of-plane with respect to the flow direction.  As a result, based upon the 
theory presented previously for the effective mechanism of the bioelectric effect, the AC 
field will increase permeability of the bacterial cells, with those cells affected the most 
being towards the bottom of the microfluidic channel and directly between the two 
electrodes.  The resultant electrophoresis provided by the presence of the DC electric 
field will apply a force upon antibiotic particles, driving them into the more permeable 
biofilm and increasing efficacy of the applied antibiotics.  Results presenting 
experimental demonstration of the SP BE at the microscale are included in Chapter 4.   
 
3.3 System-Level Design using Model-Based Systems Engineering 
The opening sections of this chapter have introduced the different design 
considerations and relevant technologies required for the development of the Micro-
BOAT system, utilized in this thesis as an example implementation of the systems 
engineering principles presented in Chapter 2 for the development of experimental 
biomedical systems.  In this section, the methodologies used to integrate these 
components is presented and the verification of particular system components is shown at 
a high level in order to demonstrate the integral use of systems engineering principles 
within the design phase of biomedical device development, specifically with respect to 
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the presented Micro-BOAT system, utilized in this work as an application of the 
proposed system.   
While high-level modeling was integral in the development of the Micro-BOAT 
system for component integration and the implementation of the on-chip superpositioned 
bioelectric treatment effect, additional lower-level simulations were required in order to 
design and validate individual system components such as the design of microfluidic 
channels, electrode design, optical electrical component circuitry, and PCB design. The 
images shown in Figure 3.8 demonstrate the modeling efforts that have led to the 
development of the physical modules of the Micro-BOAT system.   
Ray tracing analysis in the ASAP modeling paradigm (Fig. 3.8a) validated design 
of the optical components of the system, including the need for masking of the 
microfluidic channels and the corresponding CCD components in order to avoid signal 
noise and increase sensitivity.  A three-dimensional representation of the optical density 
monitoring system is created using the ASAP computer aided design (CAD) tool, and 
system parameters tuned to optimize system performance.  Simulation of microfluidic 
channel geometries using finite element modeling in COMSOL (Fig. 3.8b) was utilized to 
confirm flow characteristics within the microchannels and to avoid areas of high flow 
stress that would incur a greater risk of device leakage during operation.  Such 
simulations confirmed the theoretical calculations provided in Section 3.2.3 while also 
allowing for increased device reliability, by decreasing high-shear areas, and 
visualization of possible challenges of the interface between the microfluidic channel and 
the larger external flow tubing.  Simulations of the electric fields generated within the 
microfluidic channel for the SP BE confirmed treatment biocompatibility as well as 
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electric field intensity in vital channel regions (Fig. 3.8c).  Finally, circuit design and 
layout performed in the Cadence and EAGLE paradigms (Fig. 3.8d) confirmed CCD 
functionality and ensured proper PCB design for the integrated device system.  Such 
circuits are based upon the wiring configurations of the CCD components when utilized 
in parallel (see Appendix A) and were performed to confirm power requirements of the 
system and investigate device cross talk. 
 
 
Figure 3.8: Various modeling performed in the design and development of the 
microsystem constructed for this research.  (a) Optical detection modeling using the 
ASAP software paradigm (Breault Research Organization). (b) Fluidics modeling of a 
parallel two-chamber microfluidic system designed as an alternative to the utilized 
fluidics of the current Micro-BOAT architecture that may be implemented in future work 
(COMSOL Multiphysics, COMSOL Group). (c) Simulation of the electric fields utilized in 
the on-chip demonstration of the SP BE (COMSOL Multiphysics, COMSOL Group). (d) 
Simulation of the PCB design for six parallel charge-coupled devices (EAGLE Light 
Edition, CadSoft Computer USA and Cadence PSpice, Cadence Design Systems, Inc.).   
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Based on the analyses provided in Section 3.2 and the system-level approach 
provided by the modeling platform presented here in Section 3.3, a mapping of Micro-
BOAT device components and subsystems to system functionality can be provided.  
Table 1, below, outlines such relationships, with the details of newly introduced 
components described in further detail in Chapter 4.   
Table 1: Micro-BOAT component mapping to the system-level modeling platform for 

















 Gold Electrodes 
 Fluidic Tubing and 
Syringe Pump 
 CCD Photodetectors 














 Gold Electrodes 
 CCD Photodetectors 









 Microfluidic Growth 
Chambers 
CCD Photodetectors  Sensing Network 
Optical Ray Tracing 
Modeling (ASAP) 
 Data Acquisition 
System/Card 
 Microfluidic Growth 
Chambers (via 
biofilm growth) 
LED Light Source Sensing Network 
Optical Ray Tracing 
Modeling (ASAP) 
 CCD Photodetectors 
Data Acquisition 
System/Card 
Data Processor None 
 CCD Photodetectors 
 PCB 
 LabVIEW Data 
Readout Software 
LabVIEW Data Readout 
Software 
Data Processor None 
 Data Acquisition 
System/Card 




Not Realized Not Realized 
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The relationships presented via the “Related/Affected Micro-BOAT Components” 
column intends to show the interrelationships between various subsystems in the device 
system, and follows from figures 2.4 and 2.5.   
The parallels of Micro-BOAT components to the overall biological/biomedical 
tool’s architecture is shown further in Figure 3.9 below, which displays prototype 
versions of the Micro-BOAT subsystems as they were initially tested.   
 
Figure 3.9: High-level visual representation of the mapping between modeling platform 
elements and the physical Micro-BOAT subsystems.  Images are representative and do 
not show the physical structure of the Micro-BOAT or biofilms formed within the Micro-





This image represents general biomedical systems at an even higher level of abstraction 
than that presented in figures 2.3 and 2.5, by reducing such systems to a network of four 
interacting components: (1) a biological element (biofilm), (2) a sensor network (CCD 
components), (3) a physical system (microfluidic system), and (4) software/signal 
processing (data acquisition system/card and LabVIEW processing software).   
Using this mapping, a full device design is achieved that is capable of satisfying 
performance requirements.  Continued in the Testing and Results section of this thesis, a 
similar analysis is performed based on biological model utilized to represent development 
of a probabilistic, high-level bacterial biofilm within the microfluidic channels of the 
Micro-BOAT system. The discussion of this biological model differs from the current 
section, as this work is purely experimental and, while enabling for the future 
development of systems such as the Micro-BOAT platform presented here, did not 
directly drive the operating conditions and performance of the overall system.  Rather, 
the Micro-BOAT device, as implemented, utilized the platform methodology developed, 
while limiting its use of biological models to mathematical models estimated 
independently of the system architecture, with the results of these simulations being 
considered by the system via an additional requirement set.  Thus, the principles of the 
developed platform for the engineering of experimental biomedical devices remains a 
driving force in this effort, with the utilized mathematical model providing additional 
requirements in the Micro-BOAT design, while an empirically developed Markov Model 
is developed external of this analysis.  Future work in this application area, as described 
subsequently in this thesis, will target the continued development of the Markov Model 
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and the integration of the model with a functional model of device structure and 
performance.   
Collectively, the work presented in this chapter provides the background and 
support for full-system design of the Micro-BOAT system as well as the use of this 
system for biological and drug discovery applications such as the testing of the novel SP 
BE for bacterial biofilm treatment.  The following chapter provides the full system design 
for the device as well as the fabrication and assembly process of the developed Micro-
BOAT system.  Subsequently, Chapter 5 presents the developed model of the biological 
bacterial biofilm system, as well as testing, characterization, and use of the developed 
Micro-BOAT system for a specific drug screening application, thereby presenting a 
potential method of future bacterial infection treatment in addition to a working example 










Chapter 4: Micro-BOAT Design and Fabrication 
 
4.1 Introduction 
The following discusses the full-system design of the Micro-BOAT device that forms the 
crux of this research, as well as the fabrication and assembly processes required to 
achieve system functionality.  Figure 4.1 reiterates the full system design developed in 
this work, which was first presented at the conclusion of Chapter 1. 
 
Figure 4.1: Full-system schematic of the integrated microsystem.  The device is based on 
a PCB platform supporting system electronics, external connectors, and the charge-
coupled devices used to detect changes in biofilm optical density.  Microfluidic channels 
formed in PDMS enable six parallel experiments on a single chip.  Patterned gold 
electrical contacts enable application of the SP BE.   
 
The previous chapter of this thesis presented the systems-level analysis that contributed 
to the design of the Micro-BOAT system, achieved through the use of a modeling 
platform specifically tailored to experimental biomedical devices such as the Micro-
BOAT.  In the coming sections, each component and/or module of the system is 
discussed with regards to its final design and fabrication in order to enable future 
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optimization and use of the device for drug screening and biological study applications.  
This information provides a basis for the characterization and experimental 
demonstration of the microsystem in Chapter 5, in which the biofilm growth and 
treatment system is used to evaluate the effectiveness of the superpositioned effect 
biofilm treatment with respect to traditional biofilm treatments using exclusively liquid 
antibiotics.   
 
4.2 Device Design 
 Here we present the full design and specifications of the Micro-BOAT system, 
beginning with the lowest level substrate, the PCB module and moving towards the top-
most layer of the device, which is comprised of the PDMS-based fluidic component.  
Assembly of the system is discussed in the final section of this chapter, thus enabling full 
realization of the device.     
 
4.2.1 Printed Circuit Board and Electrical Components 
 The PCB developed for the Micro-BOAT is designed to integrate easily with 
microfluidic devices fabricated out of PDMS on a 100mm diameter wafer mold.  To meet 
this requirement while remaining small enough to fit inside of the small incubator for 
experiments, the final PCB pictured in Figure 4.2 is a 9.5 cm × 8.1 cm epoxy resin PCB 
(Advanced Circuits).  The PCB features six evenly spaced charge-coupled devices (CCD, 
TSL202R, Texas Advanced Optoelectronic Solutions) integrated in parallel to enable 
biofilm detection in six channels simultaneously and in real-time.  The PCB also features 
wiring and surface-mount electrical components to support operation of the CCD 
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components.  330Ω pull down resistors (0805 SMD, Panasonic Corporation) and 0.1µF 
capacitors (0805 SMD, TDK USA) are integrated and all external connections are 
achieved via on-chip MOLEX connectors (538-22-23-2061 and 538-22-23-2041, Molex, 
Inc), shown in black in Figure 4.1.   
 
Figure 4.2: PCB Design showing the integration of six CCD components (IC1 - IC6) in 
parallel to enable six simultaneous biofilm experiments.  The inset rectangle (shown in 
gray) defines the area covered by the electrode and microfluidic modules of the system, 
introduced in the next sections.  Red and blue lines define the wiring pattern of the PCB, 
with red lines showing top-surface wiring and blue lines showing bottom-surface wiring 
patterns.  Molex connectors (X1 - X6) allow connections to off-chip power and signal 
sources.  Surface-mount resistors (R1 – R6) and capacitors (C1 – C7) are required for 
operation of the CCD components.   
 75 
Four mounting holes on the PCB allow for suspended attachment of the fully assembled 
Micro-BOAT in the incubator (I5110, Labnet International, Inc) using ¼-inch bolts to 
avoid electrical shorts and enable easier fluid sample integration on-chip.   
 
4.2.2 On-Chip Electrodes 
 Electrodes for the application of electric fields relevant to the superpositioned 
bioelectric effect are fabricated upon the top surface of the Pyrex
TM
 substrate, allowing 
the electrodes to have direct contact with the fluids within the microfluidic channels.  In 
so doing, the insulating electrical properties of the Pyrex
TM
 and the rubber-like PDMS 
can be avoided, thus allowing for precise calculation of the electric field intensity used in 
the bioelectric treatment.   
 
Figure 4.3: Electrode design fabricated upon the PyrexTM substrate for the application 
of the SP BE.  Electrodes are configured to provide an electric field to the six parallel 
microfluidic channels of the system while simultaneously limiting peripheral light from 
entering the CCD components via a “window” pattern.  Additional dashed horizontal 
lines at the top and bottom of the PyrexTM chip are patterned in gold and provide 
guidelines for the alignment of the microfluidic PDMS slab.  Mask design is conducted 
using the software package L-Edit. 
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Seven electrodes form six individual electric field chambers and are fabricated on the 
substrate (see section 3.3.3) with 2.0 mm gap spacing.  Spaces between electrodes in the 
narrowest areas measure 0.25 mm in order to create a “window” pattern that limits 
peripheral light from entering the CCD components during biofilm OD measurement.  
Contact pads corresponding to each electrode are symmetrically patterned on each side of 
the substrate and measure 2.5 mm × 2.5 mm square.   
For the application of electric fields, electrode polarity is alternated from left to 
right between positive and negative (i.e., the left most electrode is positive, the one to its 
right negative, the next positive, and so on).  Edge effects at the ends of the active area of 
the electrode pattern are not substantial and therefore are neglected in analysis of the 
system.  Alignment marks for the bonding of the microfluidic PDMS slab are comprised 
of three patterned horizontal lines on the top and bottom of the substrate.  Fabrication of 
these electrode structures is presented in section 4.3.2.   
 
4.2.3 Microfluidic Module    
The microfluidics module developed for the Micro-BOAT system is constructed 
of PDMS on a Pyrex
TM 
substrate.  Six parallel channels are integrated on a single 
Pyrex
TM
 chip measuring 84 mm × 54 mm to accommodate the channels while 
maintaining reasonable surface area for adhesion of PDMS to the substrate.  The 
individual channels are spaced 13 mm center-to-center, with each active chamber area 
measuring 100 µm deep, 2000 µm wide, and 2 cm long.  The tapered portions of the 
chamber leading to the inlet and outlet measure 2.6 mm long and are 1000 µm wide at 
their narrowest.  Inlets and outlet holes in the channels measure 2 mm in diameter and 
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create openings through the top of the PDMS slab.  Overall the channels, including inlets 
and outlets, measure 2.9cm in length.   
 
Figure 4.4: Microfluidic channel design for the Micro-BOAT system.  Six parallel 
channels, shown in white, are integrated on a single slab of PDMS mounted on a 
PyrexTM substrate.  Mask design for the microfluidic channels is conducted using L-Edit 
(L-Edit v11.0, Tanner Research, Inc).   
 
Connections to the microfluidic channels are achieved via barbed connectors (Cole 
Parmer no 06365-15) and Tygon tubing (Cole Parmer no 95609-14) that link the 
microfluidic chambers to microcentrifuge fluid reservoirs and an external syringe pump 
(Cole Parmer 74900) operating in withdrawal mode to minimize device leakage.  The 
fabrication and assembly processes relevant to the microfluidics module of the Micro-
BOAT system are presented subsequently in section 4.3.3.   
 
4.3 Device Fabrication 
 Since the Micro-BOAT is an integrated microsystem composed of multiple 
modules, the following section discusses the unique fabrication of each system 
component separately before providing the methods used to assemble the full device.  
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Discussion of system activation and operation as well as testing apparatus is discussed in 
the following chapter.   
 
4.3.1 Printed Circuit Board and Electrical Component Assembly 
The PCB used in this work is designed using PCB-specific software (EAGLE 
Light) and subsequently commercially manufactured (Advanced Circuits) to limit manual 
fabrication.  Device assembly is required via soldering using standard tin/lead (60/40 
ratio) multicore solder wire.  Figure 4.5 provides an example of a fully-assembled PCB 
module.   
 
 
Figure 4.5: A fully assembled PCB featuring six CCD components in parallel to enable 
six parallel experiments on a single chip.  Connector pins are visible in the white Molex 
connector housings.   
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4.3.2 On-Chip Electrode Fabrication   
 Electrodes are patterned on-chip for the generation of electric fields used in the 
superpositioned bioelectric treatment effect.  The structures are microfabricated using a 
liftoff process on the Pyrex
TM
 substrate.  AZ-5214 negative photoresist (Clariant) in a 1.6 
µm thickness profile is patterned using the transparency mask pattern presented in figure 
3.2 using the process parameters provided in Table 2.  For this process, 
hexamethyldisilazane (HMDS) is not required prior to the photoresist spin as it proved to 
sufficiently adhere to the surface of the Pyrex
TM
 wafer without this step.   
Table 2: AZ-5214 Process for On-Chip Electrode Liftoff  
Step 1.6 µm thickness profile 
Hexamethyldisilazane (HMDS) None 
Spin Cycle Rate: 3000 rpm, Ramp: 500 rpm/s, Time: 30 s 
Soft Bake 60 s at 100 ºC 
Exposure 60 mJ/cm
2
 for 405 nm UV exposure 
Post-Exposure Bake 45 s at 125 ºC 
Flood Exposure 2400 mJ/cm
2
 for 405 nm UV exposure 
Development 2 min in AZ400K (1:6 dilution in DI water) 
 
For this application, in which the photoresist is developed on a transparent substrate, 
characterization and tuning of exposure parameters was required in order to obtain 
sufficient resolution of the photoresist pattern.  Following the lithography step, full-wafer 
evaporation of gold is performed in a 200 nm thickness prior to the final liftoff step.  
Evaporation of chrome/gold (Cr/Au) is performed using a Metra thermal evaporator and 
the parameters prescribed in Table 3.   
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Table 3: Chrome/Gold Deposition by Evaporation Process 




Filament Current 125 A 
Chamber Temperature > Evaporation points for Cr, Au 
 
To complete the electrode structures on the Pyrex
TM
 wafer, liftoff is performed using 
acetone as a photoresist stripper for approximately 5 minutes under agitation by 
ultrasonication.  Rinsing using DI water full prepares the patterned base for bonding to 
the microfluidic structures in PDMS.  The fully fabricated electrode devices are presented 
in figure 4.6.   
 
Figure 4.6: Photograph of fully fabricated gold electrode structures constructed on a 
PyrexTM substrate.  Bonding of the PDMS microfluidic channels is performed on the 
patterned side of the substrate to enable application of the electric fields for the SP BE 
within the channels for biofilm treatment experiments.   
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4.3.3 Microfluidic Module Fabrication  
 As discussed previously in this chapter, the microfluidic module consists of 
microfluidic channels molded in PDMS bonded to a Pyrex
TM
 substrate.  These two 
elements are fabricated separately and bonded as a last step in order to create functional 
microfluidics.  Here, we discuss the processes relevant to the fabrication of these 
channels and the steps required to achieve bonding and functional use of the microfluidic 
devices.  Specific procedures for the fabrication of the electrode-patterned Pyrex
TM
 
substrate are included in the next section.   
 A full fabrication process flow for the microfluidics and electrode modules is 
presented in Figure 4.7, with the fabrication process for the electrode patterns (Fig 4.7d – 
4.7e) following that outlined in Section 4.3.2.  
 
Figure 4.7:  Fabrication process for the microfluidic module of the Micro-BOAT system.  
Here, the procedure relevant to the fabrication of the microfluidic mold (a-b), PDMS 
molding (c), electrode fabrication (d-e) and microfluidic channel bonding (f) are 
presented in sequence. 
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The PDMS-based microfluidic channels are formed from a reusable negative mold that is 
constructed of KMPR-1050 (MicroChem Corp, USA) negative photoresist on a test 
grade, 100mm diameter single-side polished (SSP) silicon wafer.  KMPR-1050 is 
patterned using the process parameters specified in Table 4, with contact 
photolithography being performed using a transparency mask (5080dpi positive film, 
emulsion down, PageWorks, USA) mounted on a glass plate.   
Table 4: KMPR-1050 Microfluidic Mold Preparation Procedure 
Step 100 µm thickness profile 
Wafer Dehydration 10 min at 100ºC 
Spread Cycle Rate: 500 rpm, Ramp: 100 rpm/s, Time: 10 s 
Spin Cycle Rate: 1100 rpm, Ramp: 300 rpm/s, Time: 30 s 
Soft Bake 25 min at 95 ºC 
Exposure 1600 mJ/cm
2
 for 365 nm UV exposure 
Post-Exposure Bake 6 min at 95ºC 
Development 6 min in SU-8 developer 
 
Using this process, a 100 µm thickness profile is achieved corresponding to the depth of 
the microfluidic channels.  Wafer dehydration and baking processes are conducted using 
a DATAPLATE
® 
hot plate (PMC Industries, USA), with photoresist spins conducted on a 
P-6708 unit and exposure performed using a Quintel Q4000 Contact Aligner.  A contact 
profilometer (6M Surface Profiler, Veeco Dektak) is used to confirm channel geometry, 
which shows low variability (<10%) across the wafer mold, with most channels ranging 
from 95 µm to 105 µm in depth.  For this process, a post-development hard bake step was 
not required to generate permanent mold structures and the addition of such a step did not 
show any advantages in mold longevity.     
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 Prior to using the mold for the fabrication of microfluidic devices, silanization of 
the master must be performed in order to avoid adhesion of PDMS to the mold structures 
[96].  While it is often suggested that this process be utilized for the first 4-5 iterations of 
PDMS molding, verification of this technique has shown that as little as one silanization 
process is sufficient to prevent adhesion of the PDMS to the photoresist/silicon mold 
during curing.  Silanization is performed by suspending the wafer mold for one hour in a 
vacuum desiccator in the presence of approximately 4 mL of trimethylchlorosilane 
(Silane M3, Gelest, Inc) in a micro weigh boat.  Chamber pressure is reduced to 685 
mmHg to enable evaporation of the silane solution and coating of the mold.  Upon 
completion of this step, the wafer master is sufficiently protected for the molding of 
PDMS channels without the risk of fatal adhesion of the two.   
 Microchannels are fabricated using PDMS (Sylgard 184, Dow Corning) in a 10:1 
ratio that is mixed to a 35 g volume and degassed in order to remove all imbedded 
bubbles.  The silicone mixture is poured over the wafer mold and cured in a furnace 
(BF51732BC, Thermo Scientific, Lindberg/Blue M) for 20 minutes at 80 ºC.  After 
cooling, the PDMS is peeled from the mold and manually diced to size.  Ports for 
integrating the PDMS-based microfluidics with Tygon tubing are drilled through the top 
surface of the PDMS using a 2 mm-diameter dermatological punch (#BP20, HealthLink).   
 The PDMS microchannels are reversibly bonded to the patterned side of the 
Pyrex
TM
 substrate by applying methanol to the PDMS layer, then aligning and placing it 
onto the substrate until full evaporation of the methanol has occurred, thereby ensuring a 
waterproof seal between the two surfaces.  Here, reversible bonding is preferred over 
permanent methods such as oxygen plasma bonding to allow for disassembly, cleaning, 
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and reuse of the patterned Pyrex
TM
 substrate for multiple biofilm growth experiments 
[97].  Additionally, since the methanol bonding method is a reversible process, any 
misalignment in initial bonding of the microfluidic device can be easily corrected. A fully 
fabricated microfluidic module for the Micro-BOAT is presented in Figure 4.8.   
 
 
Figure 4.8: Photograph of the fully fabricated microfluidic module offering six channels 
on a single chip for parallel biofilm growth and treatment experiments.  The PDMS-
based microfluidic channels are shown here after methanol binding to the PyrexTM 
substrate with electrode structures.   
 
4.3.4 Full System Assembly  
 Full-system assembly of the Micro-BOAT incorporates the three components 
discussed in sections 4.3.1 through 4.3.3 and requires no additional fabrication.  The 
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process is presented in the following steps, with figure 4.9 providing an example of a 
fully fabricated and assembled device.   
 
Figure 4.9: Fully assembled Micro-BOAT system prior to mounting in the Labnet 
incubator.  Following this mounting process, the microfluidic channel inlets and outlets 
are connected to external fluidics for the flow of bacterial cultures and media needed to 
conduct biofilm experiments.   
 
1. Beginning with the PCB module discussed in section 4.3.1, small adhesive strips 
are cut to size and attached to the non-sensor portion of the charge-coupled 
device packaging (IC package).  These strips enable firm attachment of the 
microfluidic module to the PCB.   
2. Using the methanol binding method discussed previously, the PDMS-based 
microfluidic structures are adhered to the Pyrex
TM
 substrate with patterned gold 
electrodes.  The two structures are compressed until the methanol has fully 
evaporated in order to ensure a leak-free bond.   
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3. Visual aligning and placement of the microfluidic module is performed.  
Assembly is conducted with the Pyrex
TM
 substrate facing down, contacting the 
adhesive strips / CCD IC packages and allowing alignment of the electrode 
“windows” to the linear arrays of the CCD components.  This constitutes full 
assembly of the Micro-BOAT system.  
4. The complete device platform is mounted on the shelf in a miniature incubator 
using ¼-inch bolts.  The holes in the PCB for these mounts align to the microwell 
plate holders in the aluminum shelf of the I5110 Labnet incubator.   
After the microsystem is fully assembled, it must be connected to external fluidics to 
enable the flow of bacterial cultures, growth media, and aqueous treatment samples (i.e. 
liquid antibiotics).  To achieve this, Tygon tubing (Cole Parmer no 95609-14) with 
barbed connectors (Cole Parmer no 06365-15) interface with the fluidic channel inlets 
and outlets and are sealed using quickset two-part epoxy (no 1293758, Loctite) to prevent 
the influx of air when the system is under flow.  Fluid flow is achieved with an external 
syringe pump (Cole Parmer 74900) operating in withdrawal mode.  Fluid samples are 
contained in 1.5 mL microcentrifuge reservoirs (02-681-285, Fisher Scientific) that are 
placed in the incubator during experimental cycles in order to avoid temperature shock to 
the bacterial cultures and/or films.  A full description of device operation and 
experimental procedures is presented in the following chapter.  Figure 4.10 demonstrates 
a fully assembled Micro-BOAT system that is prepared for experimental use, including 
microfluidic connections and electrical connections for the powering of PCB-mounted 
devices and on-chip electrodes for the bioelectric treatment effect.   
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Figure 4.10: Photograph of a fully assembled and experimentally prepared Micro-BOAT 
system.  Fluidic Tygon tubing provides connections to an external syringe pump and fluid 
sample reserves, while various electrical connections to the PCB allow for powering of 
on-chip electronics components and application of electric fields for the SP BE.  In this 
image, connections between the electrodes for the bioelectric effect and the source of the 
electric field are not connected.  The LED light source (not pictured) is positioned 
directly above the complete system to provide diffused light for OD detection.   
 
In this following chapter, specific procedures for the actuation and operation of the 
device are provided, as well as experimental procedures and results obtained from 
characterization experiments and experiments comparing the novel SP BE to traditional 






Chapter 5: Testing and Results 
The following chapter presents the full testing apparatus and procedures used to 
conduct experiments in the Micro-BOAT system, including both characterization 
experiments and those testing the novel superpositioned bioelectric effect presented 
previously for biofilm treatment.  Characterization experiments effectively validate and 
verify the Micro-BOAT as a viable system for investigations involving bacterial biofilms.  
Similarly, use of the microsystem to evaluate the potential benefits of the SP BE displays 
encouraging results in which the treatment method drastically increases the efficacy of 
localized biofilm treatments in comparison to traditional antibiotic therapies.   
 
5.1 Bacterial Biofilm Markov Chain Modeling 
 The proposed platform for the modeling of experimental biomedical systems 
utilizes Markov Chain models to integrate the performance of biological systems within 
the construct of the larger biomedical system in order to determine overall system 
performance.  In enabling this platform, a focus of this work examined the efficacy of 
utilizing Markov Chian models to achieve (1) predicting and determining the 
functionality and response of biological systems and (2) of integrating these models with 
physical models of a device system.  To demonstrate this as an enabling approach to full-
system biomedical device development, a simplified architecture of a bacterial biofilm is 
implemented and demonstrated in this work.   
 In order to achieve biological modeling of the bacterial biofilm system within the 
microfluidic channels of the Micro-BOAT system, the bacterial biofilm is mapped as 
high-level segments of biofilm to the structure of the microfluidic channel.  Visually, this 
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can be represented using figure 5.1 below, which provides a conceptual abstraction of the 
biofilm within the microfluidic channel to the system level modeling via SysML or UML.      
 
Figure 5.1: Implementation of the bacterial biofilm Markov Model.  Here, biofilm within 
the microfluidic channels of the device are segmented along the channel as biofilm 
segments (1-N), each represented as a network of interdependent Markov Chains.  High-
level system modeling at the SysML or UML level facilitates alteration of the biofilm 
structure and modeling parameters.   
 
Each segment of the bacterial biofilm structure within the microfluidic channel is 
represented as a segment of biofilm modeled using a Markov Chain.  At a graph level of 
the biological system model, the biofilm segments (1-N) are interdependent upon one 
another.  Thus, the growth characteristics and trends of a single biofilm segment affect 
the segments of surrounding biofilm, thus creating a full biofilm system model that, from 
a high level, represents the biofilm growth within a microfluidic environment.  
Proceeding a level higher in abstraction, system-level engineering can provide access to 
this model as well as the ability to readily modify model parameters, such as growth 
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parameters, in order to quickly detect the effects of various changes on the biofilm 
structure.   
 In the implementation explored in this work, a simplified biofilm structure was 
explored utilizing biofilm segments that can exist in one of three biofilm growth states, 
corresponding to physical states of biofilm maturity.  Thus, each biofilm state is 
described as existing as either a depleted biofilm, a moderate biofilm, or a mature biofilm, 
corresponding to a particular level of biofilm viability.  While these terms are somewhat 
general in the context of the complicated biological system, the terms could alternatively 
correspond to physical descriptions of biofilms, e.g., a biofilm viability metric (i.e., a 
ratio of metabolically active to metabolically inactive bacteria), an average biofilm height 
metric (i.e., a height in microns or a percentage of the height of the overall microfluidic 
channel, in this case the height of the biofilm structure within a 100 µm deep channel), or 
a surface coverage metric of the biofilm structure (i.e. as a percentage of the microfluidic 
cell substrate or as an area/units
2
).  In addition to the three biofilm system states defined 
for this model, the biofilm system as a whole is defined as being dependent upon two 
global variables, which exist as a set of two environmental conditions affecting the 
development of the bacterial biofilms within the microfluidic systems.  These global 
variables are defined as including (1) nutrient concentration within the bacterial biofilm 
and the biofilm growth environment/media, and (2) biofilm surface shear stress as a result 
of fluid flow within the channels.  For this model, each of these parameters is defined as 
being one of a pair of values: either High or Low.  While defined qualitatively for this 
example, in practice, these global variables can correlate to physical values, e.g., a value 
for an oxygen concentration in terms of g/L, or a value for shear stress expressed in units 
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of Pascals or as a function of flow rate and biofilm height within the microfluidic 
channel, as expressed previously in equation (10) of this thesis.  Each of these two global 
environment variables are independent variables that affect each of the interdependent 
biofilm segments, as described subsequently.   
 In implementing the Markov Chain model of the bacterial biofilm system, each 
biofilm segment is describe according to Figure 5.2 as shown below.   
 
Figure 5.2: Markov Chain model used to implement the bacterial biofilm segments of this 
system.  Each system state of the biofilm model can propagate by only one state per 
increment of time (e.g., a depleted biofilm can become a moderate biofilm, but not a 
mature biofilm, in one increment).  The propagation probabilities are specific to the 
current state of the surrounding biofilm segments, as well as the environmental (global) 
variables.   
 
As implemented, each biofilm segment can propagate only from its current state to a state 
one ‘position’ away per iteration of the cycle.  For example, a biofilm segment that is in a 
depleted biofilm state can only remain as a depleted biofilm or propagate to a state of 
moderate biofilm, it cannot progress, in a single step, from a depleted biofilm to a mature 
biofilm.  This is done not only for computational reasons, as it drives down the number of 
potential combinations associated with the Markov Chain system, but also for logical 
reasons, as it is not natural to expect a biological biofilm system to immediately develop 
from a minimal (depleted) state to a maximal (mature) state, but rather to have to 
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progress from one to the other through an intermediate (moderate) state.  Additionally, 
while time is removed from this example and is represented only as a function of the 
number of unitless steps that the system is simulated for, the time associated with each of 
these steps, e.g., 1 hour or 1 day per step, can be tuned to match the Markov Model so as 
to most accurately represent an actual biofilm.   
 When considering the biofilm system as a whole, the biofilm segments in the 
current implementation are not interdependent in such a way that every biofilm segment 
is dependent upon every adjacent biofilm segment, i.e., that every biofilm segment i is 
dependent upon the states of the environmental conditions (global variables) as well as 
the state of biofilm segments i-1 (upstream segment) and i+1 (downstream segment).  
Rather, in order to represent a biological biofilm system in a manner that is both accurate 
and computationally simplistic, the Markov Chains representing biofilm segments 1 
through N for this implementation are dependent solely upon the upstream biofilm 
segments (i-1 segment) in addition to the environmental conditions (global variables).  In 
the case of the i=1 biofilm segment, representing the most-upstream segment of the 
biofilm, the biofilm is defined as being dependent upon the i=1segment in addition to the 
environmental conditions, in order to maintain simplicity of the model.  Overall, the 
implemented biofilm model can be visualized via Figure 5.3 below, where biofilm 
segments (1-N) are defined in addition to the interdependencies of the segments.   
 For the specific model implemented in this work and presented as demonstration 
of the efficacy of biofilm modeling using Markov Chains as a generalization of biological 
modeling using the same method, a network of 10 biofilm segments is implemented using 
the arrangements and specifications provided.   
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Figure 5.3: Graph level visualization of biofilm segments and their interdependencies as 
defined in the performed simulation.  Each box represents a singular Markov Chain 
biofilm segment, with interdependencies represented through the provided arrows.  
Environmental conditions (global variables) uniformly influence the biofilm Markov 
Chain segments.   
   
To implement the biofilm Markov Model, a Markov Model Simulation Tool developed 
by Yang, et al. and using the Java programming language is utilized in order to determine 
the probabilistic outputs of the system [75].  The developed tool enables the structure and 
transition probabilities of a specific system to be encoded, where the tool then determines 
the outcomes of the system based upon the transition probabilities and each of the 
potential combinations of variables (e.g., the environmental conditions) within the 
system.  Additionally, the tool utilizes techniques capable of recognizing model 
symmetry of the particular set of Markov Chains, and of reducing the computations 
needed to determine the outputs of the particular system based upon this symmetry [75].  
The simplified 10-segment system was chosen in order to minimize the computing 
overhead of the application, while maintaining the usefulness of the model as an example 
system for the modeling of a bacterial biofilm biological system within the microfluidic 
environment.  Full coding of the biofilm model, as utilized for this work, is presented in 
Appendix B of this thesis for further reference.  For the particular system presented here, 
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transition probabilities between the various states were determined based upon expected 
biofilm system development, supported by the relationships that determine bacterial 
biofilm growth and development, i.e., the set of partial differential equations, and 
otherwise approximated based upon the qualitative effects of shear stress and nutrient 
concentrations on bacterial biofilms.  Using the initial transition probabilities defined, the 
values were adjusted slightly to achieve a biofilm model that matches the anticipated 
output of the biological system.  The probabilities utilized for the final simulation are 
provided in Appendix B, where an abbreviated set of the code is presented, describing the 
first four segments of the 10-segment biofilm model implemented in this work.  As the 
model is symmetric for each biofilm segment, with only the connections between the 
various segments being unique, the remaining code of the biofilm segments is in this 
thesis.  Overall, through Bayesian statistics, the number of probabilities computed by the 
system are found to be: 
X = A * a * n
N
      (12) 
Where X is the total number of system states, A represents the number of global variables 
(i.e., environmental conditions), a is the number of possible states of each of the global 
variables (i.e., high and low), n represents the number of Markov Chain segments (i.e., 
biofilm segments), and N is the number of segments (i.e., the number of segments in the 
total biofilm).  For this particular model, the number of states equates to:  
X = 2 * 2 * 3
10
 = 236,196    (13) 
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Due to the symmetry in the system that is recognized using the tool developed by Yang, 
the total number of states is reduced by 25%, or a total of X = 177,147 states, or a 
reduction of 59,049 states.   
  The results of the performed simulation are presented below.  Due to the 
presence of symmetry within the model, the overall simulation was capable of being 
computationally reduced by a factor of 25%.  In Figure 5.4 below, a simulation is 
performed in order to determine the number of biofilm segments existing in each state for 
a large number of iterations (N=100) of the system for all of the four combinations of 
global variables.  Cumulatively, among the four combinations of environmental 
conditions (high shear stress – high nutrient concentrations, low shear stress – low 
nutrient concentrations, high shear stress – low nutrient concentrations, and low shear 
stress – high nutrient concentrations) 31.915% of biofilm segments exist in a depleted 
state, 41.832% of biofilm segments exist in a moderate state, and 26.252% of biofilm 
segments exist in a mature biofilm state.  This result demonstrates that the biofilm model 
designed for this system provides, at a high level, an accurate qualitative representation 
of biofilm structure.  Based on the proposed set of environmental conditions, one expects 
that biofilms subjected to limiting environmental conditions, i.e., high shear stress and 
low nutrient concentrations, will display depleted growth.  Similarly, those biofilms 
subject to growth conducive conditions, i.e., low shear stress and high nutrient 
concentrations, will display mature growth, and those biofilms subject to neutral 
environmental conditions, i.e., high shear stress and high nutrient concentrations and/or 
low shear stress and low nutrient concentrations, result in a moderate growth of biofilms.  
In this case, since there are essentially two combinations of environmental conditions 
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promoting moderate growth and one combination of environmental conditions promoting 
both depleted and mature growth, one anticipates that the ratio of moderate biofilm 
segments (41.832%) to depleted (31.915%) or mature (26.252%) biofilm segments would 
be approximately 2:1, a ratio that is supported through this high-level simulation.  In the 
Discussion chapter of this thesis, further discussion of this result, as well as its 
implications for the use of the platform for the engineering of biomedical systems as a 
whole, is presented.  The remainder of the results presented in this chapter follow from 
the model developed here, where the Micro-BOAT system is explored for its use in the 
growth of bacterial biofilms and the evaluation of various biofilm treatments, including 
the SP BE discussed as a focal point of this work.   
 
Figure 5.4: Results of the simulation conducted for a ten segment qualitative biofilm 
model based on qualitative characterization of biofilms.  The model is simulated for 
biofilm segments that are interdependent and characterized by a set of three states, being 
one of depleted, moderate, or mature biofilm.  The model is tested against two 
environmental conditions, environmental nutrient concentration and flow induced shear 
stress, each provided a binary high/low value.  
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5.2 Testing Apparatus and Actuation 
 The following section discusses the experimental setup developed for the 
actuation and use of the Micro-BOAT platform, as well as the signals required to actuate 
the device under operation.  Subsequently, characterization and demonstration of the 
device is presented as an enabling step towards the utilization of the Micro-BOAT system 
for biofilm growth and treatment experiments.   
 
5.2.1 Experimental Testing Setup  
Borrowing from the device design and fabrication presented in Chapter 4 of this 
thesis, a high-level representation of the full experimental apparatus used for the Micro-
BOAT is presented in figure 5.5.  The full system is contained within an incubator at 
37ºC to provide control of environmental conditions, which also houses fluid samples 
that are supplied to the microfluidic channels of the system and an edge-lit LED light 
panel (Luminous Film USA) that is used to uniformly illuminate the CCD components of 
the system.  Light emission is tuned to 630nm red light by a polycarbonate lighting gel 
film (Roscolux #120, Rosco Laboratories) in order to match the peak sensitivity of the 
CCD photopixels.  Interconnections via Tygon tubing connect the outlets of the 
microfluidic channels to the external syringe pump, which operates in withdrawal mode 
to prevent device leakage.  A power supply and three function generators used to actuate 
the CCD components, discussed fully in section 5.2.2, are situated outside of the 
incubator and provide the necessary electrical signals via BNC cables (L-Com Global 
Connectivity) and the PCB-mounted wire-to-board connectors.  Signal readout from the 
CCD components is achieved using a data acquisition (DAQ) device (NI USB-6221, 
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National Instruments) that integrates directly with the customized LabVIEW macro 
application developed for the application (LabVIEW 2010 SP1, National Instruments) 
running on an external PC (Optiplex 790, Dell).   
 
Figure 5.5: High-level schematic of the system’s experimental setup.  Samples and the 
Micro-BOAT system are contained in an incubator at 37ºC while an external syringe 
pump operating in withdrawal mode enables flow through the microfluidic chambers.  
External power supplies and function generators enable actuation of the CCD sensors, 
while a DAQ device and PC are used to obtain and analyze OD measurements.   
 
5.2.2 Charge-Coupled Device Operation 
Actuation of the linear pixel array CCD components is achieved via the signal 
waveforms outlined previously in section 3.2.2.  For convenience, the timing diagram for 
the TAOS TSL202R components is reproduced here.    
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Figure 5.6: Timing diagram of the TAOS TSL202R linear array charge-coupled device.  
A drive clock (CLK) in combination with an out-of-phase serial input bit (SI) triggers 
integration and output of the CCD photopixels, given as a series of analog voltages on 
the output pin of the device (AO) [90].   
 
The output of the system is governed by a drive clock (CLK) supplied by an external 
function generator (Agilent 33220A) providing a square wave signal at 150 kHz (6.67 µs 
period) with 5.0 Vpp centered at 2.5 Vdc.  Using this drive frequency, the full output of 
the 128 pixels of the CCD occurs in 0.853 ms. Clock frequency is optimized in this case 
to allow the CCD pixels to output voltages in the linear range of output for the device, 
which occurs in the 1.0 Vdc – 2.5 Vdc output range and is presented further in section 
5.3.  The serial input (SI) bit, which triggers the integration and output of the CCD 
device, is provided by a second function generator (Agilent 33220A) operating in pulse 
mode to provide a periodic signal with a 1.0 ms period, 1.5 % duty cycle, and 5 ns 
rise/fall time.  Since the active time of the SI bit (0.015 ms) is approximately the same as 
two full periods of the CLK signal (0.013 ms), there is no possibility that the SI bit will 
miss the rising clock edge needed to trigger output and next-cycle integration of the CCD 
device, despite the fact that the two signals are not triggered off of one another.  In the 
event of consecutive rising edges of the CLK signal being captured by the SI bit, 
effectively resulting in a secondary output of the CCD pixels after an integration cycle of 
only 6.67µs, the processing software described in section 5.2.3 guarantees that only the 
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relevant data will be measured and stored for analysis.  Actuation of the CCD 
components is enabled via a 5.0 Vdc source provided by an external power supply 
(Agilent E3631A).  Connections between the external power sources, function generators 
and the PCB-mounted CCD devices are achieved via BNC cables and wire-to-board 
connectors as mentioned previously.  Wiring of the individual CCD IC chips is 
performed in parallel according to specification (see Appendix A) [90].   
 
5.2.3 Data Acquisition 
 In order to perform data readout and analysis of the optical density measurements 
recorded from the six parallel CCD components, a National Instruments DAQ card and 
LabVIEW are integrated with the system to store data on a local PC.  For this application, 
a customized macro was developed in LabVIEW that allows data acquisition throughout 
a full experiment, which may last between 24 h and 72 h, with minimal user intervention.   
 The DAQ device is integrated with the device using BNC cables and wire-to-
board connectors as described previously and with the local PC via a USB connection.  
The DAQ is a 16-bit device featuring 16 parallel analog I/O channels and a maximum 
sampling rate of 250 kS/s on a single channel.  Since the device cannot sample multiple 
channels in parallel, the LabVIEW program designed for the application operates using a 
sequential method in which each of the six CCD devices is sampled in series.  While this 
is not optimal, the continuous activation of the CCD devices (e.g., the clock and serial 
input bits are continuous, with a full cycle of device operation occurring every 1.0 ms) 
and the slow changes in biofilm OD allow this method to provide accurate measurements 
of each channel at specified measurement points.    
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 The developed LabVIEW program utilizes the sampling and data analysis/storage 
schema provided in the high-level flow diagram in figure 5.7.  Appendix D provides the 
full LabVIEW documentation, including front panel interface, block diagram 
programming, and virtual instrument (VI) configuration parameters.   
 
 
Figure 5.7: High-level flow diagram of the data acquisition process using LabVIEW.  
After defining experimental operating parameters, the program initializes the required 
files, before sequentially obtaining measurements from each of the six CCD components.  
This data is then analyzed for basic metrics and appended to the proper data files.  The 
program then detects if the experiment time has been exceeded and assumes a wait phase 
until the data readout and writing processes are called upon.   
 
Operation of the LabVIEW program begins with the user input of key variables that 
define the operation of the experiment including: (1) time in minutes between 
measurements, (2) full experiment time span in hours, (3) CCD drive clock frequency, (4) 
DAQ sampling frequency, (5) number of samples to read from each DAQ channel, and 
(6) append/overwrite data from each channel.  Cumulatively, these six variables define 
how often the program should obtain data from the CCD components, how data readout 
should be performed with respect to DAQ sampling, and how the data should be stored in 
the specified files.  With these parameters set, running the program begins with the 
initialization of the data storage files.  The program then proceeds to sequentially read the 
specified number of data points from each channel, using a rising edge trigger to define 
the beginning of the CCD output from the dark voltage (approximately 0 Vdc) to the 
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active pixel output voltage (above 1.0 Vdc).  Due to the use of high-pass filtering to 
remove noise from the CCD analog output signal, the first few samples from the DAQ 
are eliminated in data analysis in order to avoid the effects of slower transitions between 
dark voltage and active voltage output signals.  Following data reads, basic analysis is 
performed on the data, including average pixel voltage output for each channel, as well as 
maxima and minima.  Average optical density measurements are obtained by collecting 
voltage data from each of the 128 pixels of the CCD and averaging their output values at 
each measurement period.  These values, as well as individual analog voltage data points, 
are then appended to the generated Excel files along with a relevant time stamp.  
Following this data write process, the system then enters a wait phase until the next 
program call for data readout, which is user-defined.  A summary of typical measurement 
processing parameters is provided in Table 5 below, although other parameter values 
were often used in preliminary experiments.  Since the NI USB-6221 DAQ is limited to 
250 kS/s, the system is unable to exceed the Nyquist rate (twice the CCD drive clock 
frequency) thereby posing a current limitation to precise data acquisition and analysis that 
can be addressed in future work [98].  Here, both 150 kS/s and 225 kS/s were used as 
sampling frequencies for the 150 kHz CCD drive clock in order to allow the highest 
accuracy of sampling with limited ghosting and noise.  Using this designed LabVIEW 
macro, successful data acquisition of six parallel channels was performed in real-time, 
thereby validating this high-throughput method for biofilm monitoring applications and 




Table 5: Typical Operating Parameters for the LabVIEW Program  
Parameter With 150kS/s sampling With 225kS/s sampling 
Time Between Measurements 8 min 8 min 
CCD Clock Frequency 150 kHz 150 kHz 
DAQ Sample Frequency 150 kS/s 225 kS/s 
# of Samples to Obtain 128 (-4 Presamples) 191 (-5 Presamples) 
Low-Pass Filter Frequency 15.0 kHz 22.5 kHz 
Trigger Threshold Voltage 0.3 V (0.25 V Hysteresis) 0.3 V (0.25 V Hysteresis) 
 
5.3 Device Characterization 
 To perform validation and verification of the developed Micro-BOAT system, a 
series of characterization studies are presented that demonstrate the sensitivity, 
capabilities, and potential limitations of the device system for the monitoring of bacterial 
biofilms via changes in optical density.  The three studies described in this section 
effectively define these characteristics for the current microsystem, thereby supporting its 
use for biofilm treatment experiments.   
 
5.3.1 Operating Region for CCD Components 
 As described previously in section 3.2.2 and equation (4), the outputs of the CCD 
components are linearly correlated to the total energy incident on the photopixels 
whenever all other variables are kept constant.  In order to verify this relationship and 
define the range of output voltages for which the relationship is applicable, an initial 
experiment was conducted in the system.  The experiment performs a sweep of 
integration periods (tint) between 0.1 ms and 50.0 ms for three different irradiance levels 
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that are achieved by covering the top of the CCD components with three filters of 
differing opacity.   
  Experiments are performed using a fully prepared microsystem that is operated 
under identical conditions to those utilized for biofilm experiments, aside from the flow 
of fluids through the microchannels, which is not required for this characterization 
procedure.  The top of the device (where LED light is incident) is covered with one of 
three adhesive films of varying opaqueness including: (1) a transparent film to define 
normal operation conditions, (2) a semi-transparent white film that absorbs 
approximately half of the light incident on the CCD components, and (3) an opaque black 
film that absorbs almost all incident light.  For each film, the integration period of the 
CCD components is varied across 25 different values ranging from 0.1 ms to 50.0 ms, 
with the CCD drive clock frequency and serial input pulse width adjusted to match the 
needs of each integration setting (e.g., a 0.1 ms integration period cannot utilize a 150 
kHz drive clock since that clock rate would require 0.83 ms to output all 128 bits of the 
CCD signal, thus resulting in unreliable device operation).  For each sample, the 
maximum CCD pixel output is recorded and plotted against the integration period, as 
shown in Figure 5.8.  Results of this experiment demonstrate a linear CCD response in 
the range of approximately 0.75 V to 3.0 V regardless of the light irradiance level, thus 
validating the use of the tool for optical density monitoring when CCD output is 
maintained within these voltage levels.  In the case of the highly opaque film, such a 
relationship is not observed as the total amount of light energy detected by the CCD 
components was too low given the tested range of integration times to allow signal 
outputs in this range.  Device saturation is observed to occur around 3.4 V and the dark 
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voltage level is demonstrated at a negligible level tending towards 0 V, both of which 
agree with device specifications [90].   
 
Figure 5.8: Maximum CCD pixel output for varying pixel integration times subject to 
three levels of irradiance.  The linear CCD output range is observed to occur from 
approximately 0.75 V to 3.0 V regardless of the irradiance level, thus validating the use 
of this system for biofilm monitoring when CCD output is maintained within these voltage 
levels.  Each data point is an average of three samples from the same CCD device on a 
fully functional Micro-BOAT. 
 
 The usable operation range of the OD detection module is defined by affirming 
the linear output region for the CCD components in the integrated system.  Biofilm 
experiments performed within the Micro-BOAT require CCD pixel outputs within the 
defined range of 0.75V to 3.0V in order to obtain results that are linearly correlated to 
changes in biofilm optical density, with the ideal initial voltage level being approximately 
2.0 V in order to provide the largest usable range for both increases and decreases in OD.   
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5.3.2 Micro-BOAT OD Measurements Correlated to Standard Methods 
A second characterization experiment demonstrates the optical density 
measurement response of the CCD components to known changes in bacterial culture 
optical density at 600nm light (OD600) in order to demonstrate device sensitivity and 
derive the relationship between optical densities measured using CCD components and 
those measured using a standardized spectrophotometry method.  The response of the 
system to known changes in optical density are provided in figure 5.9 and demonstrates a 
linear relationship between optical densities measured at OD600 and the change in optical 
density as measured using the microsystem.  This linear relationship is expected due to 
the irradiance response of the CCD photopixels presented in section 5.3.1. 
 
Figure 5.9: Correlation between optical densities measured using the Micro-BOAT and 
known OD600 values obtained from a commercial spectrophotometer.  The linear 
relationship further validates the performance of the CCD method for optical density 
monitoring and enables approximation of OD600 using the developed system.  Each data 




The use of linear regression to obtain an approximate relationship between OD measured 
using the developed instrument and OD600 as measured by a spectrophotometer allows 
the conversion of measurements made using the Micro-BOAT system to standard 
measurements using commercial devices.  Here, the slope of the curve in figure 5.9 
demonstrates that a change of 0.002 AU as measured by the CCDs (hereafter termed 
AUCCD) corresponds to a change of 1.0AU measured at OD600 (hereafter termed AUSOD).  
The linear correlation between OD600 values measured from the spectrophotometer and 
the CCD OD measurements permit calculation of the detection limit of the system as well 
as the approximation of spectrophotometer-measured OD600 using the Micro-BOAT 
device.  The device detection limit is calculated using the following equations and 
specifications supplied by the CCD manufacturer for device noise limits:  

Detection Limit (AU) 
Noise Limit (V )
Sensitivity of Device (V /AU)
     (15) 

Detection Limit (AUCCD) 
Noise Limit (V )
Sensitivity of Device (V /AUSOD)
   
            

Detection Limit (AU) 
1.0 mV
10.5 mV /AU
 0.095 AU      (16) 







Detection Limit (AUCCD) 
1.0 mV
10.5 mV /AUSOD
 0.095 AUSOD  

Detection Limit (AUCCD) 
1.0 mV
10.5 mV /AUSOD
 0.095 AUSOD 

Detection Limit (AUCCD) Detection Limit (AUSOD) Conversion Factor      (17) 
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
Detection Limit (AUCCD)  0.095 AUSOD  0.002  0.00019 AUCCD 
From this, we see that the theoretical detection limit for changes in sample OD600 is 
0.095AUSOD, which equates to a CCD-measured OD detection limit of 0.00019 AUCCD.   
 To perform this experiment, E. coli BL21 pGFP samples were prepared and the 
optical density of these samples tested using a spectrophotometer to determine OD600 in 
AUSOD.  Samples are then repeatedly diluted by a factor of 2 in LB media to generate the 
spectrum of known optical densities shown in figure 5.9.  To test the sensitivity of the 
CCD biofilm monitoring system, each of these samples was briefly inoculated in the 
microfluidic channel in order of increasing optical density and OD measurements 
recorded using the Micro-BOAT system.  Deionized water is used to flush the channel of 
bacterial cells between each sample.  Average optical density measurements are 
calculated by averaging the outputs of the 128 photopixels over a series of 25 
measurements and by using equation (6) provided in section 3.2.2.   
 
5.3.3 Demonstration of Spatiotemporal Detection Capabilities  
 Spatiotemporal detection of biofilm growth and treatment is a critical advantage 
of the developed system, as it provides additional insight into the stochastic nature of 
biofilms that is difficult to obtain using established methods.  To verify use of the device 
for the spatiotemporal detection of biofilm development within the microfluidic channels, 
a characterization experiment demonstrates the monitoring of optically dense droplets 
flowing through the microchambers of the system in real-time.  To perform this test, 
samples of deionized water were prepared in a 25:1 ratio with a green propylene glycol 
dye (McCormick & Company, Inc) to create a homogeneous solution with a measured 
 109 
OD600 of 20.3 AUSOD.  Since optical density values above 1.0 AUSOD are outside of the 
linear range of the spectrophotometer, the OD600 of this solution was measured by first 
diluting the initial mixture by a factor of 40 (overall water to dye concentration of 
1000:1) and recording its optical density, then multiplying this value by the dilution ratio.  
Droplets of the dye solution are inserted in a flow stream of translucent mineral oil by 
puncturing the Tygon tubing used for sample flow with a 27-gauge, 0.5-inch needle 
(Becton, Dickinson and Company) and injecting the droplets into the flow stream.  The 
flow of oil with separated, water-based droplets is provided at a volumetric flow rate of 
0.25 mL/h and detected using the Micro-BOAT as described previously in Section 5.2.3.   
 Results of this detection experiment are provided in figure 5.10, which displays 
both the spatiotemporal and averaged changes in optical density due to droplet flow 
within the microfluidic channel.  The measured flow velocity of droplets within the 
microchannel concurs with theoretical calculations given the channel geometry and 
volumetric flow rate of the experiment, thereby validating the device’s use for detecting 







Figure 5.10: (a) Average change in optical density within one microfluidic chamber of 
the Micro-BOAT due to the flow of optically dense droplets in a translucent fluid.  (b) 
Spatiotemporal detection of droplet flow within the same microfluidic channel. The 
enhanced waterfall plot is obtained via a customized MATLAB script (see Appendix C) 
based on the GridFit plug-in.       
 
5.4 Biofilm Treatment Experiments 
 Upon validating the optical density monitoring capabilities of the Micro-BOAT, 
the device is utilized for a series of experiments testing the relative efficacy of various 
 111 
methods of biofilm treatment, including the viability of the SP BE for the treatment of 
bacterial films.  Cumulatively, these experiments aim in demonstrating the enhanced 
treatment effects of the SP BE in comparison to treatment by antibiotics alone.  
Demonstration of this treatment in microscale environments emulating in vivo conditions 
enables its use for potential clinical applications in the future.  Furthermore, use of the 
integrated Micro-BOAT system for biofilm growth and treatment experiments validates 
its use and sensitivity for bacterial growth and treatment monitoring.   
 
5.4.1 Bacterial Strains Used 
E. coli BL21 is frequently used in clinically relevant bacterial studies, as this 
species is a well-studied microbiological system and well-suited for protein 
overexpression [99].  It has been used extensively with both native and heterologous 
proteins and provides a high protein yield per culture volume. In this study, E. coli BL21 
modified with a plasmid encoding green fluorescent protein (pGFP) is used for bacterial 
biofilm studies to enable fluorescence microscopy in which metabolically active bacteria 
fluoresce green when excited by ultraviolet light.  To conduct the experiments presented 
in this work, bacterial cultures are initially grown to an OD600 of 0.25 AUSOD.  All 
cultures are grown in LB growth media.   
 
5.4.2 Bacterial Biofilm Treatments Tested 
The testing of biofilm treatments using the microsystem developed in this work 
focuses principally upon the SP BE and its demonstration at the microscale.  As defined 
previously in section 2.4, the electric field utilized for the SP BE is comprised of an AC 
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and DC signal characterized to be a 1.25 V/cm sinusoidal signal at 10 MHz with a 1.25 
V/cm DC component that is applied to the established biofilms via thin-film gold 
electrodes patterned on the substrate of the microfluidic module.  To conduct the 
treatment evaluation study, four distinct methods were compared to determine their 
relative efficacy and demonstrate the prospective suitability of the SP BE for bacterial 
infection treatment.  The first of these treatments represents a control, in which bacterial 
biofilms are not treated using either antibiotics or electric fields, but rather are 
continuously supplied nutrient-rich LB growth media in order to provide a consistent 
growth environment.  The second method utilizes traditional antibiotic therapy, where 
gentamicin sulfate (Invitrogen Inc, USA) is applied to established biofilms at a 
concentration of 10 µg/mL in LB media [45].  A third treatment method utilizes only the 
superpositioned electric field utilized for the SP BE without the presence of antibiotics in 
order to determine the biocidal effects of applying SP electric fields to biofilms.    The 
use of this combinatorial electric field in the presence of traditional antibiotics, known as 
the superpositioned bioelectric effect, represents the fourth treatment used in this study 
[45, 94].  For this treatment, both the antibiotic concentrations and applied electric fields 
utilize the same parameters specified for antibiotic- and electric field-only treatments and 
demonstrate use of the SP BE for biofilm treatment.  These four treatments are performed 
simultaneously within the biofilm growth and treatment microsystem and are repeated 
three times in order to determine the efficacy of each method.  Detailed experimental 
procedures are provided in the following section.  
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5.4.3 Experimental Procedures 
Testing is performed by initially creating E. coli bacterial suspensions with an 
OD600 of 0.25 AUSOD in LB media.  Small quantities of frozen cell cultures maintained at 
a temperature of -80 ºC are introduced to 10 mL of LB growth media and incubated at 
37ºC in a shaker for approximately 24 hours in order to foster bacterial multiplication and 
maturation.  The bacterial suspension, which typically has an optical density in the range 
of 4.0 AUSOD, is then diluted in LB media to an OD600 of 0.25 AUSOD measured by a 
commercial spectrophotometer (Beckman Coulter Inc).    
To sterilize the microfluidic channels before placing the bacterial suspensions, 
experimentation is begun by initially disinfecting each channel using 70% ethyl alcohol 
under flow.  After rinsing with deionized water, the channel is inoculated with the 
bacteria suspension for 2 hours without flow to allow for bacterial attachment to the 
microfluidic substrate [6].  LB media is then continuously supplied to the channel for 24 
hours at 20 µL/h, an effective flow velocity of 30 µm/s given the dimensions of the 
microfluidic chamber, to replenish nutrients and facilitate biofilm growth.  Sources of LB 
media are replaced as needed in order to avoid contamination and maintain steady supply 
to the developing biofilms within the microfluidic channel.  Treatments are started after 
24 hours of growth as described previously and continued for an additional 24 hours.  To 
achieve the exchange of fluid sources during experiments with minimal effects, flow is 
stopped and the inlet tubing quickly transferred to the new source before reinitializing 
flow.   
Optical density measurements are taken non-invasively in real-time with respect 
to both average and localized changes in biofilm optical density as described previously 
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in section 5.2.  Initial optical absorbance of the biofilm is measured 30 minutes after the 
preliminary inoculation period has ended and the flow of LB media has begun.  
Measurements are obtained every 8 minutes and recorded using LabVIEW.  For the 
length of experiments used in this work, which approach 48 hours, and the amount of 
data collected in each data read cycle, the frequency of measurement at 8 minutes is 
limited by the current data storage capabilities of the developed macro application in 
LabVIEW.  Future work can utilize more advanced data storage techniques in the 
LabVIEW interface in order to increase the size limits of these data files, thereby 
increasing the frequency of measurement used in this work.  However, due to the slow 
rate of change of bacterial biofilms as biological systems, in which the doubling time is 
metabolically limited to 20 minutes under ideal conditions, an 8-minute measurement 
interval is acceptable for determining both morphological and overall changes in film 
optical density.   
In addition to the quantification of biomass changes using optical density 
measurement, the efficacy of each treatment method is further evaluated at the end of the 
experiments by a conventional cell viability quantification assay using live/dead cell 
staining and fluorescence microscopy.  Red cells in the biofilms are stained red, while 
metabolically active bacteria appear green based on the expression of green fluorescent 
protein.  To perform dead cell staining at the conclusion of the biofilm experiments, the 
microfluidic channel is first rinsed with phosphate buffer solution (PBS) at a rate of 200 
µL/h for 1 hour in order to remove non-adherent bacterial cells.  The remaining biofilm is 
then treated using a red fluorescent propidium iodide stain (Invitrogen no L7012) to 
allow imaging of the dead bacteria in the biofilm structures.  The stain is provided in a 
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1.5 µL per 1000 µL PBS concentration at a rate of 200 µL/h for 2 hours in order to ensure 
complete staining of non-living cells.  Subsequently, the channel is rinsed using PBS at 
200 µL/h for 1 hour to remove unabsorbed propidium iodide, thereby limiting imaging 
background noise caused by the presence of residual dye.  Microscopy is performed using 
a fluorescent microscope (Olympus BX60) at 20× magnification.  Both total and green 
fluorescence images are obtained from multiple locations within each labeled sample 
(N=7 for each of the treatment 3 samples, corresponding to 21 images per unique 
treatment).  Quantitative analysis of the images is performed using the image processing 
software ImageJ (Image J 1.44, USA).  After the green fluorescence mode images of the 
biofilm are filtered to remove any red and blue color hues, the image undergoes a binary 
image conversion with respect to the green fluorescence color to produce a black-and-
white image.  Similar steps are performed (using only blue hue filtering) to provide 
binary interpretations of the bright field fluorescence images of the biofilms, such as that 
shown in Figure 5.11 below.   
  
 
Figure 5.11: Example of the bright field binary conversion using the image processing 
software ImageJ.  An initial bright field fluorescence image (a) is filtered and converted 
to a binary black-and-white image (b) to enable quantitative analysis of biofilm growth 
and treatment.     
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The percentage of viable bacteria is calculated based on the surface coverage of green 
fluorescence with respect to the total fluorescent surface coverage obtained from the 
binary image conversions.  For each sample that is imaged for live/dead cell staining 
studies, 7 points within the microfluidic channel are imaged in order to obtain results that 
are representative of the average biofilm state within that channel.   
Following experimentation, system component disposal and cleaning is 
performed to enable reuse of critical system modules for future biofilm experiments.  
Bacterial suspensions, used syringes, connection tubing, and the PDMS channels are 
disposed of, while the patterned Pyrex
TX
 substrate and other remaining system 
components are cleaned for immediate reuse.   
 
5.4.4 Biofilm Monitoring by Optical Density Measurement    
Using the Micro-BOAT system as a testing apparatus, the four biofilm treatments 
presented in section 5.4.2 are performed.  For each treatment, three samples were tested 
in order to determine the relatively efficacy of each.  The result presented in Figure 5.12 
provides the change in overall optical density of the biofilms due to treatment.  Following 
the 24-hour growth period, the optical densities of each sample are normalized to an 
initial starting point (0.0 AU), with subsequent changes being represented with respect to 
this point.  Therefore, this figure provides the change in average optical density during 
the treatment phase for each therapy method, correlating to similar changes in bacterial 
biomass.  As anticipated, the control and superpositioned electric field-treated biofilms 
demonstrate increases in optical density corresponding to further biofilm growth and an 
increase in biofilm mass.  At the conclusion of the treatment phase, control biofilms 
averaged a 0.007 AUCCD increase in overall optical density, while those treated only by 
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electric fields without antibiotics demonstrated an average increase in optical density of 
0.004 AUCCD.  Standard biofilm treatment using the antibiotic gentamicin demonstrated a 
net decrease in averaged optical density of 0.003 AUCCD, representing a reference for the 
efficacy of current bacterial infection treatments.  By comparison, treatment using the SP 
BE displays an overall biofilm optical density decrease of 0.008 AUCCD, a 167% increase 
in treatment efficacy over traditional antibiotics alone.  This result verifies the capability 
of the SP BE to induce substantial biomass inhibition with respect to currently available 












Figure 5.12: Measured changes in biofilm optical density during treatment using the 
Micro-BOAT system.  Each curve represents the average optical density change for three 
samples with standard deviations shown at representative time points.  The differences in 
optical density are statistically significant (ANOVA P<0.001).   
 
 In addition to the absolute change in optical density of biofilms over the course of 
treatment, calculations were performed to determine percentage changes in optical 
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density as a result of the different therapies.  Figure 5.13 provides this result, in which the 
optical density of the sample at the conclusion of the treatment phase is presented as a 












Figure 5.13: Relative changes in bacterial biomass as a result of the performed 
treatments.  Overall, control biofilm samples demonstrated a 260% average increase in 
bacterial biomass during the treatment phase of the experiments, while those treated 
using only electric fields increased by an average of 140%.  Gentamicin effectively 
reduced bacterial biomass by 24% during treatments and the SP BE achieved the 
greatest decrease in biofilm mass with a 40% average decrease during the treatment 
phase of experiments. 
 
Cumulatively, these two results demonstrate the capabilities of the Micro-BOAT to 
determine the relative efficacies of various biofilm treatments.  Further analysis of these 
results is reserved for the discussion portion of this chapter in Section 5.4.    
 In addition to providing results that compare the relative efficacy of the performed 
treatments based upon changes in average optical density, the spatiotemporal monitoring 
capabilities of the optical density method provide insight to qualitative changes in 
localized biomass OD and the resulting biofilm structural morphologies that accompany 
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each of the tested treatments presented in this work.  As provided in Figure 5.14, control 
samples and those treated only with the SP electric field (shown) without antibiotics tend 
to develop widespread, thicker biofilms with areas of high-density biomass.  Samples 
treated with antibiotics generally demonstrate thinner biofilms with fewer clusters of 
high-density film at the conclusion of treatment, while those treated with the enhanced 
bioelectric effect display extremely limited surface coverage and even thinner layers of 























Figure 5.14: Surface reconstruction of biofilm surface morphology showing (a) 
stationary biofilm and (b) biofilm drifting through the channel with time.  The surface 
reconstruction is created using the spatiotemporal data from CCD optical density 
measurement using the Micro-BOAT system.  This particular plot is from a biofilm 
sample treated only using the SP electric field used for the SP BE without antibiotics.    
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5.4.5 Results using Cell Viability Studies 
 In addition to the quantification of biofilm growth via optical density 
measurement in the Micro-BOAT system, each of the treatments is evaluated for efficacy 
using the live/dead cell staining method presented in section 5.4.3 for further verification.  
Dead cells in the bacterial biofilms are stained red, while metabolically active cells 
appear green based upon the expression of green fluorescence protein by the E. coli BL21 
pGFP bacteria.  Figure 5.15 presents representative images of each biofilm treatment 
used in this work.  Left column (a)-(d) images demonstrate bright field fluorescence of 
biofilms after each treatment while right column images (e)-(h) present live cell green 
fluorescence for each of the four treatments.  The bright fluorescence images correspond 
to the two-dimensional projection of overall biofilm mass in the microfluidic channel 
following treatment, where both live and dead cells are visible due to fluorescence.  
Similarly the green fluorescence images provide a two-dimensional projection of the 
overall biomass with respect to only those cells that are metabolically active.  As shown 
in Figure 5.15(d), biofilms treated using the SP BE display the lowest amount of bacterial 
biomass following treatment, demonstrating the enhanced effect of this method compared 
to traditional antibiotic treatment.  Additionally, biofilms treated with the SP BE in the 
microfluidic chambers show a lower density of live cells compared to the other 
treatments, as seen in Figure 5.15(h).  Therefore, we see that this method is capable of 
reducing not only the total amount of biofilm mass, but also of reducing the viability of 
biofilms by decreasing the percentage of live cells within the biofilm structure.   
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Figure 5.15: Representative bright and green fluorescence microscopy images of biofilms 
in the microfluidic channels after treatment.  The total biomass and mass of live bacteria 
are shown for control biofilms (a,e), biofilms treated solely with the SP electric field (b,f), 
samples treated only with antibiotics (c,g), and biofilms treated with the SP BE (d,h).  
Biofilms treated using the SP BE showed less overall biofilm mass (d), as well as low live 
bacterial cell density (h).   
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The microscopy images of other treatments further demonstrated that the use of biocidal 
therapies produced thinner, more sporadic biofilms with low viable cell density, while 
control samples and those treated only with the SP electric field demonstrated more 
mature biofilm structures with considerably higher densities of both overall biofilm mass 
and live bacterial cells.   
Using the image processing procedure described previously, binary 
transformations of each total (bright field) and green fluorescence image are created in 
order to quantify the percentage of viable bacteria within biofilms treated using each 
method.  By calculating the surface coverage of the green fluorescence image with 
respect to the total surface coverage of the fluorescing biomass, the ratio of live to dead 
bacterial cells can be determined for each biofilm (Fig. 4.16).   
 
Figure 5.16: Results of cell viability studies.  The percentage of viable bacteria with 
respect to the total bacterial biomass is calculated following treatment using the image 
processing software ImageJ.  The results include the average of seven (7) images from 
each of three (3) samples for each treatment method.  The SP BE showed the highest 
efficacy of the four treatments, with a 56% increase in dead cell density compared to 
antibiotic treatment (ANOVA, P=0.019).   
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Results demonstrate that biofilms treated using the SP BE showed the lowest percentage 
of viable bacteria after treatment, with 80% of bacterial cells being metabolically 
inactive.  This is compared to traditional antibiotics, which showed 51% of bacteria are 
non-living after treatment, treatment using only the SP electric field, which demonstrated 
that 55% of biofilm bacteria were non-living, and control samples, in which an average of 
48% of biofilm bacteria were metabolically inactive after the treatment phase of 
experimentation.  The 56% increase in dead cell density present in biofilms treated using 
the SP BE poses strong evidence for the efficacy of this new method for localized biofilm 
treatment as well as the inhibition of total biofilm mass, discussed further in the coming 
discussion.     
 
5.5 Discussion 
 The following provides a discussion of the various results presented in this thesis, 
with the aim of providing analysis and further insight into the future utilization of this 
work for related studies in the various regimes discussed, including further developments 
in the use of systems engineering approaches towards the engineering of systems for 
experimental biomedical applications.   
 
5.5.1 Markov Modeling of Biofilm Systems 
The modeling presented here for a high-level structure of a bacterial biofilm 
system forms a basis for the future use of Markov Chain techniques to represent 
biological systems in full system models of biomedical devices.  Here, the biofilm model 
utilized qualitative descriptions of bacterial biofilms (depleted, moderate, mature) and 
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segmentation in order to represent a biofilm system as it exists within a microfluidic 
environment.  A graph level of Markov Chain cells was demonstrated, showing the 
method by which the segments of bacterial biofilm can interact.  Cumulatively, the 
biofilm system, represented by this interacting Markov Chain system, stands as a 
foundation for the future development of this model to describe bacterial biofilms.  The 
model has demonstrated results that conform to expectations when subjected to a set of 
two environmental conditions, specifically flow-induced shear stress and available 
nutrient concentrations within the microfluidic environment.   
 Future developments and implementations of this model can enable more accurate 
predictions of bacterial biofilm development that include additional environmental 
conditions affecting the growth and development of bacterial biofilms, as well as 
potential treatment variables that may, for example, be able to predict the efficacy of a 
candidate treatment upon an established bacterial biofilm, such as those related to clinical 
infections.  To develop such a model, data from prior bacterial biofilm studies can be 
integrated in an established model structure such as that presented here.  Through 
learning techniques, such as iterative learning techniques including the Viterbi method 
and others, this data can be utilized to tune the transition states as well as the transition 
probability values of the system, overall resulting in a biofilm model that is more 
representative of the biological system.  While it is desired that such a model would be 
uniform across any number of environments, e.g., microfluidic, in vivo, and macro-scale 
flow cells, and bacteria types, e.g., E. coli and Pseudomonas, there is a certain likelihood 
that such a model would also need to be tuned depending upon the application.  In such a 
case, biofilm models describing the system for a particular environment and a particular 
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bacteria type may exist, in which the general structure of the system remains the same, 
with only slight parameters being variant depending upon the application space.  Future 
work in the area of biological system modeling using Markov Chains can aid in the 
development of specific models for bacterial biofilms, in addition to other biological 
systems of interest, and can eventually result in a library of relevant biological models 
that can be used across disciplines in order to enable optimized studies of biological 
systems, the prediction of biological system development to enable enhanced insight into 
systems, or, with respect to the application presented here, further optimization of 
biomedical devices designed with a detailed biological system in mind.   
 In order to fully enable the optimized development of biomedical devices for 
experimental applications, models such as the high-level, qualitative bacterial biofilm 
model presented here must be integrated with physical models of the device system.  To 
achieve this, future work in this area will target the interfacing of these two model types 
through a common medium, thus allowing both models to be accessible, viewable, and 
configurable through a single port.  For the systems-based development of biomedical 
devices, as discussed throughout this thesis, a prime candidate for such integration is 
through an established system modeling language, such as SysML or UML.  By 
interfacing physical system models (such as that of the Micro-BOAT device subsystems) 
with biological models (such as the biofilm model), a full-system view is achieved that is 
not currently available using present techniques.  At the present, biomedical devices are 
designed by either (i) simulating a biological system under a set of environmental 
conditions and inserting characteristics or constraints related to this biological system in a 
functional model of a device system, or (ii) simulating the functionality of a device 
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system and modeling a biological system based on the environmental or other conditions 
the biological system is subject to, based on the operation of the device.  Through an 
integrated approach, a truly unified model of the full experimental biomedical system is 
achieved.  Ideally, through the successful integration of the two models in a medium such 
as SysML or UML, a developer from either the biological or engineering regime can 
access the model, adjust parameters relevant to the model, and determine the effects of 
such changes upon the operation of the system as a whole in terms of both its biological 
and device systems.   
 In order to achieve this final goal, future work must focus on two central areas.  
First, the use of various modeling mechanisms, such as the proposed Markov Modeling 
scheme presented here, must be explored and evaluated in further detail for efficacy, 
accuracy, and efficiency in modeling stochastic biological systems such as the bacterial 
biofilm system explored in this work.  Secondly, the interfacing of a biological model, 
developed in a specific modeling paradigm or using a specific modeling method, with a 
physical system model must be addressed.  While the development of individual models 
representing both the physical system and the biological system are critical for the unified 
design of biomedical devices for experimental applications, it is the integration of these 
two mechanisms that is required for the truly successful system engineering of device 
systems for experimental biomedical applications.  Without such an interface, the 
disconnect between biological and engineering regimes is not truly addressed, thus 
leaving the development of biomedical devices to choose a stronghold in one regime or 
the other, without a truly integrated approach to optimized system design.  By developing 
such an interface, or set of interfaces, however, the bridge between biological and system 
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domains is fully completed, and a new generation of biomedical devices optimized for 
their specific application can be pursued concurrently by both biologists and engineers.  
 
5.5.2 Micro-BOAT System 
 Here we have demonstrated biofilm monitoring via CCD components to provide 
insight into both average and localized changes in biofilm optical density.  Physical 
changes in biofilm structure, such as localized growth, detachment, or the aggregation of 
free-flowing biofilm particulates over an established biofilm structure are detectable 
using the microsystem, a principle advantage of this tool over currently available 
technologies.  While other methods such as confocal microscopy may provide higher 
resolution of biofilm structure and morphology in comparison to the optical density 
approach presented here, biofilm measurements using these systems are limited strictly to 
end-point measurements in which the samples must be labeled and imaged after 
experiment completion.  In comparison, the OD measurement demonstrated in this work 
through the integrated Micro-BOAT system is capable of performing label-free in situ 
biofilm measurement in order to provide additional information with respect to time-
variant biofilm characteristics.  Additionally, the Micro-BOAT system is capable of 
providing similar measurements as those achieved using other optical density tools, 
including commercially available spectrophotometers, and at a fraction of the cost of 
these systems [100].  While the device detection limit of the Micro-BOAT system (DL = 
0.0019 AUCCD) is less than that of commercially available systems, which typically have 
detection limits on the order of 0.01 AUSOD, the low cost and ability of the Micro-BOAT 
to determine real-time net changes in optical density as opposed to end-point values 
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remains an advantage of this system.  This method also enables the correlation of optical 
density measurements using the Micro-BOAT tool (ODCCD) to other common methods, 
such as optical absorbance at 600 nm (ODSOD), with limited calibration.  As mentioned, a 
principle advantage of this tool lies in the capabilities of the system to monitor these 
changes spatially and in real-time.  As shown in Figure 4.10, the Micro-BOAT is capable 
of performing full-channel imaging of the biofilm structures continuously in order to 
determine both average changes in the naturally variant biofilms, as well as changes with 
respect to biofilm morphology and surface coverage.  The non-specific detection 
achieved through broad-spectrum optical density analysis makes this an ideal method for 
evaluating the efficacy of treatments, including the superpositioned bioelectric effect 
presented here, on a number of clinically relevant bacterial strains without the need for 
specialized labeling.  The additional advantages enabled by the use of microfluidics in the 
Micro-BOAT system to reduce reagent volumes, increase testing rates and environmental 
control, and enable high-throughput testing substantiate this system as an advancement of 
current methods.  Based on the advantages of optical density measurement using the 
Micro-BOAT system and the advantages of detecting biofilms grown and treated in 
microfluidic environments, the system can advance fundamental and drug discovery 
research efforts, including those aimed at the development of new biofilm treatment 
methods.    
 
5.5.3 Superpositioned Bioelectric Effect Biofilm Treatment 
 Using the Micro-BOAT system as a testing instrument, this work has 
demonstrated improved efficacy of biofilm treatment at the microscale through the use of 
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an enhanced bioelectric effect that combines traditional antibiotic treatments with 
externally applied, SP electric fields.  Using a superpositioned electric field characterized 
to be well within biocompatible limits and below the media electrolysis potential, this 
treatment produced repeatable results averaging a 167% greater reduction in bacterial 
biomass compared to traditional antibiotics as measured by the average change in biofilm 
OD for each treatment.  Affirmation of these results using microscopy and image analysis 
reveals that this method not only reduces total biofilm mass, but also the ratio of live to 
dead cells within the remaining biofilms.  Compared to standard antibiotic therapy using 
gentamicin, biofilms treated with the SP BE demonstrated a 56% increase in dead 
bacterial cell density.  Such a metric is vital to quantifying the enhanced biofilm 
treatment of gentamicin in conjunction with the SP electric fields, as it enables the 
determination of a new MIC value for this specific treatment.  While this value has not 
yet been determined, it is clear that the MIC of gentamicin for the SP BE is below both 
the current MIC of ~32 µg/mL and the gentamicin concentration utilized in this work of 
10 µg/mL [101, 102].  The cumulative effect of biomass reduction and cell viability 
reduction using this enhanced treatment method suggests it is a strong candidate for 
future biofilm treatments, both clinical and non-clinical in nature.   
 While enhanced biofilm treatment using the SP BE has been demonstrated 
previously within our group at the macroscale using milliliter reagent volumes, the 
demonstration of this method at the microscale using a device featuring planar, thin-film 
electrodes encourages the prospective use of this technique for various clinical 
applications including the in vivo treatment of bacterial infections.  The size reduction of 
the SP BE was a necessary transition in the realization of this method for these clinical 
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uses, since a microscale device is required for any implantable applications that arise.  
Additionally, scaling of the device dimensions to micrometer ranges was necessary in 
order to achieve the electric fields required for effective biofilm treatment while 
maintaining voltage potentials within biocompatible limits and below that of media 
electrolysis.  By applying biocompatible electric fields in the presence of lower, 
sustainable doses of antibiotics, infection treatment efficacies are achievable that are 
traditionally realized only through the use of much higher antibiotic concentrations or 
invasive surgery.  Additionally, current results suggest that the use of the SP BE can not 
only increase the efficacy of such treatments, but also the rate at which biofilm reduction 
takes place.  As seen in Figure 8, treatment using the SP BE has a near immediate effect 
on biofilm mass, causing reductions within the first few hours of treatment, while therapy 
using antibiotics exclusively requires a longer period for treatment to commence, 
typically on the order of five to ten hours.  The rapid onset of treatment using this new 
method can aid in early treatment of biofilm infections once detected, thereby mitigating 
the risks associated with such infections.  Forward-looking applications of this treatment 
for in vivo applications can utilize micro-devices with integrated planar electrodes such as 
those featured in the Micro-BOAT system in order to achieve localized biofilm treatment 
in areas at high threat of bacterial biofilm development, such as medical implants, 
catheters, urinary tracts, dental cavities, and others.  By applying localized treatment 
through the SP BE, antibiotic concentrations can be adjusted to sustainable levels by 
creating highly lethal concentrations of antibiotics in areas that have succumb to bacterial 
infections, thereby reducing the proliferation of antibiotic resistance, while limiting the 
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concentrations of these antibiotics in other areas within the body to much lower levels 
[103-105].   
 While the superpositioned bioelectric effect has demonstrated improved biofilm 
treatment efficacy in both macro- and micro-scaled applications, understanding of the 
fundamental mechanisms of this treatment method remains in preliminary stages.  Recent 
work with respect to the bioelectric effect utilizing only DC electric fields suggests that 
the electrophoretic force induced by this electric field can create a gradient of the charged 
antibiotic molecules, thereby effectively forcing greater amounts of antibiotics into the 
biofilm structure [106-108].  Similarly, the application of an AC bioelectric effect is 
believed to increase the permeability of individual bacterial cells by inducing molecular 
vibrations in the cell membranes, thus enabling antibiotics to infiltrate and affect bacteria 
more readily [109, 110].  Building upon these suggestions from the literature, by 
combining these two mechanisms one can both increase the concentration of antibiotics 
within the targeted biofilm (DC component) as well as the effectiveness of these 
antibiotics by enabling them to more readily affect bacteria comprising the biofilm (AC 
component).  This notion supports future work to improve the efficacy of the SP BE to 
achieve treatment levels on par with the biofilm reduction observed in macroscale 
applications, which demonstrated efficacy on the order of two orders of magnitude 
reduction in biofilm mass [45].  While these macroscale applications utilized uniformly 
distributed electric fields perpendicular to the biofilm growth substrate, the Micro-BOAT 
features 0.2 µm planar thin-film gold electrodes in a 100 µm deep microfluidic channel, 
thereby inducing a non-uniform electric field within the microchannel [111].  The applied 
electric field decreases in intensity from the channel substrate towards the top of the 
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channel due to the inversely proportional relationship between field intensity and distance 
from the electrodes.  Although the induction of a non-uniform electric field toward the 
top area of the channel reduces the biocidal effects of the SP BE compared to the 
uniformly applied field utilized in macroscale experiments, the thin-film electrodes 
utilized by this system enable a reduction in device dimensions that is critical for future 
implantable treatment system development [94].  Therefore, the future implementation of 
electrodes capable of uniform electric field induction may further enhance the efficacy of 
this treatment method at the microscale, in turn allowing the further reduction of 


















Chapter 6: Summary and Future Direction 
6.1 Research Summary 
 Two principle thrusts were pursued through this research work: (1) the 
development of a Micro-BOAT system for biofilm investigations including those for 
drug discovery, and (2) the adaptation of a novel SP BE to the microscale to enable future 
applications of this method for bacterial infection treatment.  Overall, both of these goals 
have been demonstrated through this work and provide a strong basis for the future 
development of microsystems for drug discovery applications and the continued 
investigation of the SP BE for antimicrobial infection treatments in clinical applications.   
 The developed Micro-BOAT device is an integrated system that provides a 
microfluidic environment for bacterial biofilm growth offering added control of 
experimental growth conditions, of expediting drug screening processes through parallel 
testing and reduced assay times, and of decreasing the cost of drug screening efforts by 
reducing necessary reagent volumes.  Through the use of one-dimensional linear array 
charge-coupled devices integrated with the microfluidic biofilm growth chambers, optical 
density monitoring of biofilm growth and treatment is achieved that enables the non-
invasive, real-time, label-free measurement of biofilms in situ.  This capacity constitutes 
a novel capability of this technique providing critical advancements over established 
methods including confocal microscopy and spectroscopy by commercially available 
systems.  By integrating these devices with external software, six parallel experiments 
contained on a single chip can be monitored and measured simultaneously.  The system 
demonstrated an OD detection limit of 0.0019 AUCCD, which enables the spatiotemporal 
tracking of average changes in bacterial growth and correlates to an OD600 detection limit 
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of 0.095 AUSOD.  The capability of the Micro-BOAT system to monitor these 
spatiotemporal changes in biofilm optical density provides further insight into the 
stochastic nature of bacterial biofilms during growth and treatment that is currently 
unavailable using established monitoring methods.  The ability of the system to perform 
such measurements continuously and in real-time is a principle advantage of the Micro-
BOAT system over current methods, which are typically limited to end-point biofilm 
measurements.  Overall, the Micro-BOAT represents a stand-alone system capable of the 
parallel growth and treatment of bacterial biofilms and temporal, spatially realized 
monitoring of biofilms through an optical density approach providing added capabilities 
over currently available technologies.   
 By integrating planar, thin-film gold electrodes with the microfluidic channels of 
the Micro-BOAT system, an enhanced biofilm treatment method utilizing 
superpositioned AC and DC electric fields in the presence of antibiotics was 
demonstrated showing significantly improved efficacy over traditional antibiotic 
treatments.  On average, biofilms treated using the SP BE showed a 167% reduction in 
overall biomass compared to traditional antibiotic therapies, as measured by the change 
in biofilm optical density during experimental treatments.  In addition to the improved 
biomass reduction realized through this method, biofilms treated with the SP BE also 
display a reduction in cell viability following treatment.  Fluorescence microscopy 
studies performed at the conclusion of biofilm experiments display that those samples 
treated by the SP BE average a 56% increase in dead cell density compared to traditional 
antibiotic therapies using only gentamicin.  The on-chip validation of this method in a 
microscale device has far-reaching impacts by enabling its use for future clinical 
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applications, including the treatment of bacterial infections.  Reduction of electrode 
geometries to the micrometer regime enables the treatment mechanism for implantable 
devices, while the small size of these structures allows the potentials required for the SP 
BE to be reduced to levels within biocompatible limits and below media electrolysis.  
Overall, the demonstration of the SP BE utilizing thin-film electrodes in a microsystem 
directs the further development of an implantable device for in vivo biofilm infection 
treatment, while the Micro-BOAT as a whole represents a new research tool for scientific 
biofilm studies including drug discovery and antimicrobial mechanism investigations.   
 Throughout the development phase of this work, systems engineering analyses 
played a vital role in the design and characterization of system components and their 
integration.  Thorough requirements analysis of the proposed system resulted in a 
modular architecture comprised of: (1) a PCB base to house parallel CCD components 
and supporting electronics, (2) a transparent substrate with micropatterned gold 
electrodes to limit light extraneous to the OD measurement and apply the SP electric 
fields, and (3) a PDMS-based microfluidic module to provide biofilm growth chambers.  
Low-level modeling of optical, fluidic, electromagnetic, and electronic components 
verified proper system operation and enabled optimization of component design 
parameters.  The top-down approach utilized in this work achieved full system 
integration of the various modules and software resulting in a novel tool for the 
spatiotemporal monitoring of bacterial biofilms.  As discussed in the following section, 
this architecture is adaptable to future generations of the device system to enable 
expanded capabilities of the Micro-BOAT without complete system redesign, a critical 
advantage of the system-level development performed in this work.   
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6.2 Future Research Directions 
 The work presented here provides a foundation for the future advancement of 
technologies relating to both biofilm optical density measurement in devices such as the 
Micro-BOAT, as well as those relating to enhanced biofilm treatment using the SP BE.  
By advancing these two areas through short- and long-term goals, the benefits of this 
engineering research can have far reaching impacts on the biomedical field with respect 
to scientific studies of bacterial biofilms, including antibiotic development applications, 
and the emergence of new treatment methods for bacterial infections.      
 With respect to the Micro-BOAT system and similar devices utilizing CCD 
components in microsystems to perform optical density monitoring of bacterial biofilms, 
short-term research directions primarily concern increasing the reliability and precision of 
the system, as well as the expansion of detection capabilities to two dimensions.  While 
the theoretical noise limits of many CCD ICs lies in the sub-millivolt range, the current 
system is subject to slightly higher noise levels on the order of several millivolts due to 
the circuitry and external wiring required to support the Micro-BOAT system.  By 
lowering these noise levels, optical density detection limits can be reduced, thereby 
increasing the sensitivity of the biofilm monitoring system.  Similarly, improvements in 
the methodology used to drive the CCD system and sample optical density measurements 
can improve device performance and overall system reliability.  To achieve these 
improvements, several key areas should be addressed including: (1) synchronization of 
the LED light source and CCD activation to produce a discrete light pulse as opposed to 
the currently used continuous lighting, (2) synchronization of CCD drive clock, serial 
input, and sampling, and (3) integration of an improved data acquisition card capable of 
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parallel channel sampling (as opposed to the single channel sampling capability of the 
current DAQ) and of sampling rates well above the Nyquist rate of the CCD output.  
Additional studies may also investigate variations in the geometry of the microfluidic 
biofilm growth chambers in order to optimize the system for biofilm growth.  In doing so, 
treatment efficacies can be more readily detected by the system, since thicker, more 
developed biofilms will display a greater change in optical density if effectively treated.  
In order to increase the precision of the system, light filters or gratings may be useful in 
reducing the effects of light scattering, which provides a current limitation in the ability 
of the device to detect changes in OD of biofilm located directly above a particular CCD 
pixel.  Finally, the short-term adaptation of the current system to accommodate a two-
dimensional CCD component is also of immediate interest, since the use of such a device 
to perform biofilm monitoring can provide additional data, including such metrics as 
average biofilm surface coverage, not achievable using the current linear array device.   
 In the long-term, microsystems such as the integrated Micro-BOAT system 
presented here should be fully enclosed systems requiring minimal user interaction to 
perform precisely guided experiments.  On-chip fluidic reservoirs and lighting will 
eliminate the current needs for external equipment, thereby enabling a fully autonomous 
lab-on-a-chip device.  Additionally, the integration of microfabricated photopixels on the 
device substrate can enable improved biofilm optical density monitoring by providing 
precise sensor alignment, higher sensitivity, and reduced reliance on external 
components.   
 Future work in the development of the superpositioned bioelectric effect 
concerns, in the near term, investigation of the mechanism of this method that leads to 
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enhanced biofilm treatment and further confirmation of its biocompatibility for clinical 
applications.  While the results presented here provide strong support of this method for 
the prevention and treatment of bacterial infections, the precise mechanism leading to the 
increased efficacy of antibiotics when in the presence of AC and DC electric fields is not 
yet fully understood.  Before clinical applications of this method can be pursued in 
earnest, the mechanism of treatment enhancement must be investigated and its origins 
fully understood.  Building upon this immediate need, other future work must investigate 
the biocompatibility and possible side effects of this treatment method as applicable to 
clinical applications.   
 With these areas satisfied, the long-term research focus of the SP BE concerns the 
integration of this method in medical devices for the localized treatment of bacterial 
infections in vivo.  By implementing this treatment method for clinical applications, such 
as on medical implants or catheters, a new era of biofilm treatment may be realized that 
can reduce the health risks of surgery and of bacterial infections, limit the required intake 
of antibiotics in infected patients, and stunt the proliferation of antibiotic resistive 
bacteria in the clinical realm.  Towards this goal, preliminary work in the verification of 
this treatment method can pursue the integration of thin-film surface electrodes on 
microscale devices, followed by testing in both in vitro and in vivo environments in order 






Appendix A – TAOS TSL202R Specification 
Device Functionality:  
 
 













Appendix B – Biofilm Simulation using the Markov Chain Modeling Tool  
Machine: Nutrient 
  State: low labels: level=low 
    p[low] = 1/2, p[high]=1/2 
  State: high labels: level=high 
    p[low] = 1/2, p[high]=1/2 
 
Machine: ShearStress 
  State: low labels: level=low 
    p[low] = 1/2, p[high]=1/2 
  State: high labels: level=high 
    p[low] = 1/2, p[high]=1/2 
 
Machine: Film0 
  State: little labels: level=little 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film1::level=little       p[little] = 4/5, p[moderate] = 1/5 
      else if Film1::level=moderate  p[little] = 1/2, p[moderate] = 1/2 
      else                           p[little] = 1/5, p[moderate] = 4/5 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if      Film1::level=little    p[little] = 1/2, p[moderate] = 1/2 
      else if Film1::level=moderate  p[little] = 1/5, p[moderate] = 4/5 
      else                           p[little] = 1/10, p[moderate] = 9/10 
    else  // nutrient low shear high // inhibit 
      if      Film1::level=little    p[little] = 9/10, p[moderate] = 1/10 
      else if Film1::level=moderate  p[little] = 4/5, p[moderate] = 1/5 
      else                           p[little] = 7/10, p[moderate] = 3/10 
  State: moderate labels: level=moderate 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film1::level=little       p[little] = 3/5, p[moderate] = 3/10, p[large] = 1/10  
      else if Film1::level=moderate  p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10 
      else                           p[little] = 1/5, p[moderate] = 3/10, p[large] = 1/2 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film1::level=little       p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10  
      else if Film1::level=moderate  p[little] = 1/5, p[moderate] = 2/5, p[large] = 2/5  
      else                           p[little] = 1/10, p[moderate] = 3/10, p[large] = 3/5 
    else  // nutrient low shear high // inhibit 
      if   Film1::level=little       p[little] = 1/2, p[moderate] = 2/5, p[large] = 1/10  
      else if Film1::level=moderate  p[little] = 3/10, p[moderate] = 1/2, p[large] = 1/5 
      else                           p[little] = 1/5, p[moderate] = 1/2, p[large] = 3/10 
  State: large labels: level=large 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film1::level=little       p[moderate] = 4/5, p[large] = 1/5  
      else if Film1::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 3/10, p[large] = 7/10 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film1::level=little       p[moderate] = 3/5, p[large] = 2/5  
      else if Film1::level=moderate  p[moderate] = 3/10, p[large] = 7/10 
      else                           p[moderate] = 1/10, p[large] = 9/10 
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    else  // nutrient low shear high // inhibit 
      if   Film1::level=little       p[moderate] = 9/10, p[large] = 1/10  
      else if Film1::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 1/2, p[large] = 1/2 
 
Machine: Film1 
  State: little labels: level=little 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film2::level=little       p[little] = 4/5, p[moderate] = 1/5 
      else if Film2::level=moderate  p[little] = 1/2, p[moderate] = 1/2 
      else                           p[little] = 1/5, p[moderate] = 4/5 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if      Film2::level=little    p[little] = 1/2, p[moderate] = 1/2 
      else if Film2::level=moderate  p[little] = 1/5, p[moderate] = 4/5 
      else                           p[little] = 1/10, p[moderate] = 9/10 
    else  // nutrient low shear high // inhibit 
      if      Film2::level=little    p[little] = 9/10, p[moderate] = 1/10 
      else if Film2::level=moderate  p[little] = 4/5, p[moderate] = 1/5 
      else                           p[little] = 7/10, p[moderate] = 3/10 
  State: moderate labels: level=moderate 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film2::level=little       p[little] = 3/5, p[moderate] = 3/10, p[large] = 1/10  
      else if Film2::level=moderate  p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10 
      else                           p[little] = 1/5, p[moderate] = 3/10, p[large] = 1/2 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film2::level=little       p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10  
      else if Film2::level=moderate  p[little] = 1/5, p[moderate] = 2/5, p[large] = 2/5  
      else                           p[little] = 1/10, p[moderate] = 3/10, p[large] = 3/5 
    else  // nutrient low shear high // inhibit 
      if   Film2::level=little       p[little] = 1/2, p[moderate] = 2/5, p[large] = 1/10  
      else if Film2::level=moderate  p[little] = 3/10, p[moderate] = 1/2, p[large] = 1/5 
      else                           p[little] = 1/5, p[moderate] = 1/2, p[large] = 3/10 
  State: large labels: level=large 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film2::level=little       p[moderate] = 4/5, p[large] = 1/5  
      else if Film2::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 3/10, p[large] = 7/10 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film2::level=little       p[moderate] = 3/5, p[large] = 2/5  
      else if Film2::level=moderate  p[moderate] = 3/10, p[large] = 7/10 
      else                           p[moderate] = 1/10, p[large] = 9/10 
    else  // nutrient low shear high // inhibit 
      if   Film2::level=little       p[moderate] = 9/10, p[large] = 1/10  
      else if Film2::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 1/2, p[large] = 1/2 
 
Machine: Film2 
  State: little labels: level=little 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film3::level=little       p[little] = 4/5, p[moderate] = 1/5 
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      else if Film3::level=moderate  p[little] = 1/2, p[moderate] = 1/2 
      else                           p[little] = 1/5, p[moderate] = 4/5 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if      Film3::level=little    p[little] = 1/2, p[moderate] = 1/2 
      else if Film3::level=moderate  p[little] = 1/5, p[moderate] = 4/5 
      else                           p[little] = 1/10, p[moderate] = 9/10 
    else  // nutrient low shear high // inhibit 
      if      Film3::level=little    p[little] = 9/10, p[moderate] = 1/10 
      else if Film3::level=moderate  p[little] = 4/5, p[moderate] = 1/5 
      else                           p[little] = 7/10, p[moderate] = 3/10 
  State: moderate labels: level=moderate 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film3::level=little       p[little] = 3/5, p[moderate] = 3/10, p[large] = 1/10  
      else if Film3::level=moderate  p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10 
      else                           p[little] = 1/5, p[moderate] = 3/10, p[large] = 1/2 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film3::level=little       p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10  
      else if Film3::level=moderate  p[little] = 1/5, p[moderate] = 2/5, p[large] = 2/5  
      else                           p[little] = 1/10, p[moderate] = 3/10, p[large] = 3/5 
    else  // nutrient low shear high // inhibit 
      if   Film3::level=little       p[little] = 1/2, p[moderate] = 2/5, p[large] = 1/10  
      else if Film3::level=moderate  p[little] = 3/10, p[moderate] = 1/2, p[large] = 1/5 
      else                           p[little] = 1/5, p[moderate] = 1/2, p[large] = 3/10 
  State: large labels: level=large 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film3::level=little       p[moderate] = 4/5, p[large] = 1/5  
      else if Film3::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 3/10, p[large] = 7/10 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film3::level=little       p[moderate] = 3/5, p[large] = 2/5  
      else if Film3::level=moderate  p[moderate] = 3/10, p[large] = 7/10 
      else                           p[moderate] = 1/10, p[large] = 9/10 
    else  // nutrient low shear high // inhibit 
      if   Film3::level=little       p[moderate] = 9/10, p[large] = 1/10  
      else if Film3::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 1/2, p[large] = 1/2 
 
Machine: Film3 
  State: little labels: level=little 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film4::level=little       p[little] = 4/5, p[moderate] = 1/5 
      else if Film4::level=moderate  p[little] = 1/2, p[moderate] = 1/2 
      else                           p[little] = 1/5, p[moderate] = 4/5 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if      Film4::level=little    p[little] = 1/2, p[moderate] = 1/2 
      else if Film4::level=moderate  p[little] = 1/5, p[moderate] = 4/5 
      else                           p[little] = 1/10, p[moderate] = 9/10 
    else  // nutrient low shear high // inhibit 
      if      Film4::level=little    p[little] = 9/10, p[moderate] = 1/10 
      else if Film4::level=moderate  p[little] = 4/5, p[moderate] = 1/5 
      else                           p[little] = 7/10, p[moderate] = 3/10 
 145 
  State: moderate labels: level=moderate 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film4::level=little       p[little] = 3/5, p[moderate] = 3/10, p[large] = 1/10  
      else if Film4::level=moderate  p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10 
      else                           p[little] = 1/5, p[moderate] = 3/10, p[large] = 1/2 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film4::level=little       p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10  
      else if Film4::level=moderate  p[little] = 1/5, p[moderate] = 2/5, p[large] = 2/5  
      else                           p[little] = 1/10, p[moderate] = 3/10, p[large] = 3/5 
    else  // nutrient low shear high // inhibit 
      if   Film4::level=little       p[little] = 1/2, p[moderate] = 2/5, p[large] = 1/10  
      else if Film4::level=moderate  p[little] = 3/10, p[moderate] = 1/2, p[large] = 1/5 
      else                           p[little] = 1/5, p[moderate] = 1/2, p[large] = 3/10 
  State: large labels: level=large 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film4::level=little       p[moderate] = 4/5, p[large] = 1/5  
      else if Film4::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 3/10, p[large] = 7/10 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film4::level=little       p[moderate] = 3/5, p[large] = 2/5  
      else if Film4::level=moderate  p[moderate] = 3/10, p[large] = 7/10 
      else                           p[moderate] = 1/10, p[large] = 9/10 
    else  // nutrient low shear high // inhibit 
      if   Film4::level=little       p[moderate] = 9/10, p[large] = 1/10  
      else if Film4::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 1/2, p[large] = 1/2 
 
Machine: Film4 
  State: little labels: level=little 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film0::level=little       p[little] = 4/5, p[moderate] = 1/5 
      else if Film0::level=moderate  p[little] = 1/2, p[moderate] = 1/2 
      else                           p[little] = 1/5, p[moderate] = 4/5 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if      Film0::level=little    p[little] = 1/2, p[moderate] = 1/2 
      else if Film0::level=moderate  p[little] = 1/5, p[moderate] = 4/5 
      else                           p[little] = 1/10, p[moderate] = 9/10 
    else  // nutrient low shear high // inhibit 
      if      Film0::level=little    p[little] = 9/10, p[moderate] = 1/10 
      else if Film0::level=moderate  p[little] = 4/5, p[moderate] = 1/5 
      else                           p[little] = 7/10, p[moderate] = 3/10 
  State: moderate labels: level=moderate 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film0::level=little       p[little] = 3/5, p[moderate] = 3/10, p[large] = 1/10  
      else if Film0::level=moderate  p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10 
      else                           p[little] = 1/5, p[moderate] = 3/10, p[large] = 1/2 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film0::level=little       p[little] = 3/10, p[moderate] = 2/5, p[large] = 3/10  
      else if Film0::level=moderate  p[little] = 1/5, p[moderate] = 2/5, p[large] = 2/5  
      else                           p[little] = 1/10, p[moderate] = 3/10, p[large] = 3/5 
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    else  // nutrient low shear high // inhibit 
      if   Film0::level=little       p[little] = 1/2, p[moderate] = 2/5, p[large] = 1/10  
      else if Film0::level=moderate  p[little] = 3/10, p[moderate] = 1/2, p[large] = 1/5 
      else                           p[little] = 1/5, p[moderate] = 1/2, p[large] = 3/10 
  State: large labels: level=large 
    if (Nutrient::level=low /\ ShearStress::level=low) \/ (Nutrient::level=high /\ 
ShearStress::level=high) 
      if   Film0::level=little       p[moderate] = 4/5, p[large] = 1/5  
      else if Film0::level=moderate  p[moderate] = 3/5, p[large] = 2/5 
      else                           p[moderate] = 3/10, p[large] = 7/10 
    else if Nutrient::level=high /\ ShearStress::level=low  // growth 
      if   Film0::level=little       p[moderate] = 3/5, p[large] = 2/5  
      else if Film0::level=moderate  p[moderate] = 3/10, p[large] = 7/10 
      else                           p[moderate] = 1/10, p[large] = 9/10 
    else  // nutrient low shear high // inhibit 
      if   Film0::level=little       p[moderate] = 9/10, p[large] = 1/10  
      else if Film0::level=moderate  p[moderate] = 3/5, p[large] = 2/5 

















Appendix C – Optical Density Measurement MATLAB Analysis Scripts 
%MATLAB SCRIPT TO CREATE 3D WATERFALL IMAGE OF TREATMENT O.D. DATA 
 
%Grab file data and set variables 
close all; 
data = DLMREAD(‘File_Name.csv', ',');  %read in the .CSV file  
 
x=186;     %SET X TO BE THE NUMBER OF SAMPLES PER GRAB!  
y=8;       %SET Y TO BE THE NUMBER OF MINUTES BETWEEN EACH SAMPLE GRAB!  
 
%1st Task: Organize data into matrix that MATLAB can work with 
[A, B]=size(data);        %create 2x1 matrix with A= # rows, B= # 
columns voltage=zeros(x, A/x);        
%voltage is 2D array with x rows and 
(A/x) columns, which is the number of 
times I have grabbed data (x = number of 
samples per grab).  'zeros' initializes 
the array to all 0s  
timestamp=0;                  %initialize time = 0 as a starting point  
  
values = zeros(A,3); 
  
c=1; d=1;           %counters 
j=1; 
  
timestamp=0:(y/60):((((A/x)-1)*y)/60);        
%first value is that the experiment 
starts at t=0.  middle value (increment) 
is the fraction of an hour between each 
grab.  Last value is the final grab time 
in hours.   
Position=(0:1:(x-1))*84.9/1000;        
%first term divides the data points into 
a   physical location. second term 
multiplies each location by a distance 








 Task: Perform data analysis on the formatted matrix  
for S = 1:A           %start at top of the csv file, parse down 
    values(S,2) = (x*(84.9/1000))-(p*(84.9/1000));  
%write the position value (x-axis) as a 
multiple of (p*length of each pixel) 
    values(S,1) = (q*(y/60));  
%write the time value (y-axis)as a 
multiple of (q*hours between grabs)  
    values(S,3)=abs(log10(data(S,3)/data(p,3)));    
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%calculate change in OD for the z-axis 
(data) || value next to data(S,#) is the 
column with the needed data 
    p=p+1; 
        if p==(x+1) 
            p=1; 
            q=q+1; 
        end  
end 
             


















zlabel('Change in Optical Density (AU)') 
title(‘Test_Title’) 
 
%4th Task: Save the output data for future use and analysis  





















%MATLAB SCRIPT TO CREATE TIMELAPSE IMAGES FOR GIF ANIMATION 
 
%Grab file data and set variables 
close all; 
data = DLMREAD(‘File_Name.csv', ','); %Read in the .CSV data file 
  
x=186;          %SET X TO BE THE NUMBER OF SAMPLES PER GRAB!  
y=0.016;        %SET Y TO BE THE NUMBER OF MINUTES BETWEEN EACH SAMPLE 
GRAB!  
device=2;       %SET TO THE COLUMN OF THE CSV WITH THE DEVICE DATA  
 
%1st Task: Organize data into a matrix that MATLAB can work with  
[A, B]=size(data);            %create 2x1 matrix with A= # rows, B= # 
columns  
voltage=zeros(x, A/x);        
%voltage is 2D array with x rows and 
(A/x) columns which is the number of 
times I have grabbed data (x = number of 
samples per grab).  'zeros' initializes 
the array to all 0s  
averageold = []; 




j=1;                  %counters 
  
  
timestamp=0:(y/60):((((A/x)-1)*y)/60);        
%first value is that the experiment 
starts at t=0.  Middle value (increment) 
is the fraction of an hour between each 
grab.  Last value is the final grab time 
in hours.   
Position=(0:1:(x-1))*84.9/1000;        
%First term is divides the data points 
into a physical location. Second term 
multiplies each location by a distance 
along the channel 
 
%2nd Task: Perform data analysis and plot each O.D. image   
for R = 1:A 
voltage((x+1)-j,c)=abs(log10(data(R,device)/data(j,device)));        
%voltage((x+1)-j,c) flips the order of 
the pixels so they are in their real 
locations (data reads out in reverse 
order)   
    j=j+1; 
        if j==(x+1) 
             
            yy = smooth(voltage(:,c), 101, 'sgolay', 2);  
             
%Plot and store each O.D. image 
area(Position, yy, 'FaceColor', [1 0 0]);   
            axis([ 0 15.73 0 0.2]); 
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            xlabel('Position (mm)', 'FontSize', 14); 
            ylabel('Change in Optical Density (AU)', 'FontSize', 14); 
title('Spatiotemporal Detection via Micro-BOAT', 
'FontSize', 14); 
            set(gcf, 'color', 'white'); 
            set(gcf, 'PaperSize', [10 6]); 
            set(gca, 'color', [.99 .99 .985]);   
%This color code creates a white background!!!  
            drawnow;  
            pause(0.0) 
            j=1; 
            c=c+1; 
  
            %Store the generated image 
            frame = getframe(gcf);  
            frameasimg = frame2im(frame); 
imwrite(frameasimg, sprintf('spatialtest%d.tif', (c-1)), 
'tiff'); 
                
                         
            %3rd Task: Plot and store average OD at each time point  
            avgod = mean(voltage(:,(c-1))); 
            timestep = (c-1)*y; 
            averagenew = [averageold ; timestep avgod]; 
            averageold = averagenew; 
            avgavg = smooth(averagenew(:,2), 11, 'sgolay', 2); 
             
            plot((averagenew(:,1)), avgavg,'r', 'LineWidth', [2.0]); 
            axis([0 3 0 .1]); 
            xlabel('Time (min)', 'FontSize', 14); 
            ylabel('Averaged Change in O.D. (AU)', 'FontSize', 14); 
            title('Average Change in OD with Time', 'FontSize', 14); 
            set(gcf, 'color', 'white'); 
            set(gcf, 'PaperSize', [10 6]); 
            set(gca, 'color', [.99 .99 .985]);   
%This color code creates a white background!!!  
            drawnow; 
 
            %Store the generated image 
            frameavg = getframe(gcf);  
            frameavgimg = frame2im(frameavg); 
imwrite(frameavgimg, sprintf('avgtest%d.tif', (c-1)), 
'tiff'); 
         
        end 





Appendix D – LabVIEW Control Program 
Note: This appendix supplies low-level coding of the various LabVIEW functions 
required to perform data acquisition and analysis. High-level LabVIEW operation is 
provided in Figure X.X of this thesis.   
Section A: Data Storage File Initialization 
1 of 2: File Initialization 
 
2 of 2: File Initialization 
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Section B: Data Acquisition Method  
 First CCD shown here.  Same code duplicated in series for 6 devices.   
 






Section C: Data Storage Mechanisms 
 Average Optical Density data storage in a single table.  
 
 1 of 2: Average Optical Density data from 6 CCD devices stored in a single file. 
 
 2 of 2: Average Optical Density data from 6 CCD devices stored in a single file 
 








Section D: Timing Mechanisms 
 System experiment clock.  
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